Search for: "Bristol-Myers Squibb"
Bristol-Myers Squibb and Pfizer Inc Evaluate Unmet Need in Patients with Atrial Fibrillation
HSMN NewsFeed,
25 Aug 2010:
Biopharmaceuticals, Cardiology[Bristol-Myers Squibb, Pfizer, AVERROES Trial, apixaban, atrial fibrillation]
Ipilimumab Receives FDA Priority Review Designation for Adult Patients with Previously Treated Advanced Melanoma
HSMN NewsFeed,
18 Aug 2010:
Biopharmaceuticals, Oncology, FDA[Bristol-Myers Squibb, ipilimumab, melanoma]
European Commission Approves ORENCIA in Combination with Methotrexate for Earlier Use as First-Line Biologic after DMARD Inadequate Response for the Treatment of Rheumatoid Arthritis
HSMN NewsFeed,
7 Jul 2010:
Biopharmaceuticals, Regulatory[Bristol-Myers Squibb, ORENCIA, abatacept, rheumatoid arthritis]
Lux Biosciences Names Dean Mitchell President and CEO
HSMN NewsFeed,
1 Jul 2010:
Biopharmaceuticals, Ophthalmology, Personnel[Lux Biosciences, voclosporin]
Zymeworks Closes $3.2 Million Round of Financing and Announces the Addition of Dr. Donald Drakeman to Its Board of Directors
HSMN NewsFeed,
29 Jun 2010:
Biopharmaceuticals, Venture Capital, Personnel[Zymeworks]
BioElectronics Welcomes New Additions to Marketing Team
HSMN NewsFeed,
23 Jun 2010:
Devices, Personnel[BioElectronics, ActiPatch]
Spectrum Pharmaceuticals Appoints James E. Shields as Chief Commercial Officer
HSMN NewsFeed,
23 Jun 2010:
Biopharmaceuticals, Personnel[Spectrum Pharmaceuticals]
Exelixis Regains Full Rights to Develop and Commercialize XL184
HSMN NewsFeed,
21 Jun 2010:
Biopharmaceuticals[Exelixis, Bristol-Myers Squibb, XL184, MET inhibitor]
APP Pharmaceuticals Announces Approval and Launch of First Generic Aztreonam for Injection, USP
HSMN NewsFeed,
21 Jun 2010:
Biopharmaceuticals, Generics, FDA[APP Pharmaceuticals, Fresenius Kabi Pharmaceuticals, Aztreonam, Azactam]
Tranzyme Pharma and Norgine Sign License Agreement for Late-Stage Development Product, Ulimorelin (TZP-101), in Europe and Other Select Regions
HSMN NewsFeed,
16 Jun 2010:
Biopharmaceuticals, Licensing[Tranzyme Pharma, Norgine, ghrelin agonist, TZP-101, Ulimorelin]
Alnylam Strengthens Management Team with New Key Appointments
HSMN NewsFeed,
2 Jun 2010:
Biopharmaceuticals, Personnel[Alnylam Pharmaceuticals]
Cleveland BioLabs Adds Regulatory Affairs Expertise to Development Team
HSMN NewsFeed,
24 May 2010:
Biopharmaceuticals, Personnel[Cleveland BioLabs]
AMAG Pharmaceuticals, Inc. Appoints Gary J. Zieziula as Executive Vice President and Chief Commercial Officer
HSMN NewsFeed,
27 Apr 2010:
Biopharmaceuticals, Personnel[AMAG Pharmaceuticals, Feraheme, ferumoxytol]
Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa)
HSMN NewsFeed,
26 Apr 2010:
Biopharmaceuticals, Neurology, Acquisitions[Aton Pharma, Bristol-Myers Squibb, LODOSYN, carbidopa, Parkinson's disease]
Mylan Announces Approval Under PEPFAR for Generic Version of Videx(R) EC HIV Treatment
HSMN NewsFeed,
19 Apr 2010:
Biopharmaceuticals, Generics, HIV/AIDS, FDA[Mylan, Matrix Laboratories, Didanosine, Bristol-Myers Squibb, Videx]
OXiGENE Appoints Tamar D. Howson and Peter J. Langecker to Its Board of Directors
HSMN NewsFeed,
5 Apr 2010:
Biopharmaceuticals, Personnel[OXiGENE]
Merck Serono: Erbitux Granted Extended Use in Japan for 1st-Line Treatment of mCRC Patients with KRAS Wild-Type Tumors
HSMN NewsFeed,
29 Mar 2010:
Biopharmaceuticals, Oncology[Merck Serono, Merck KGaA, Erbitux, cetuximab, mCRC]
ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer
HSMN NewsFeed,
17 Mar 2010:
Biopharmaceuticals, Oncology[Abraxis BioScience, paclitaxel, non-small cell lung cancer]
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)
HSMN NewsFeed,
9 Mar 2010:
Biopharmaceuticals, Cardiology, Endocrinology[Bristol-Myers Squibb, AstraZeneca, ONGLYZA, saxagliptin, diabetes]
Bristol-Myers Squibb and Allergan Enter Global Agreement on Investigational Neuropathic Pain Medicine
HSMN NewsFeed,
3 Mar 2010:
Biopharmaceuticals, Neurology, Licensing[Bristol-Myers Squibb, Allergan, AGN-209323, neuropathic pain]
Bristol-Myers Squibb Names Lamberto Andreotti CEO, Effective May 4; James Cornelius to Retire as CEO, Remain as Chairman
HSMN NewsFeed,
2 Mar 2010:
Biopharmaceuticals, Personnel[Bristol-Myers Squibb]
FDA Advisory Committee Recommends Approval of Belatacept, an Investigational Agent for Prophylaxis of Acute Rejection in De Novo Kidney Transplant Patients
HSMN NewsFeed,
1 Mar 2010:
Biopharmaceuticals[Bristol-Myers Squibb, belatacept]
Cadence Pharmaceuticals Receives Complete Response Letter from FDA for Intravenous Acetaminophen NDA
HSMN NewsFeed,
11 Feb 2010:
Biopharmaceuticals, FDA[Cadence Pharmaceuticals, intravenous acetaminophen, OFIRMEV, acetaminophen]
KineMed Broadens Collaboration with Bristol-Myers Squibb
HSMN NewsFeed,
8 Feb 2010:
Biopharmaceuticals, Personalized Medicine, Neurology[KineMed, Bristol-Myers Squibb, Alzheimers disease]
Noven Appoints Patrick Gallagher as Vice President
HSMN NewsFeed,
3 Feb 2010:
Biopharmaceuticals, Personnel[Noven Pharmaceuticals]
Sensors for Medicine and Science, Inc. Names Dr. Paul Strumph as Chief Medical Officer
HSMN NewsFeed,
2 Feb 2010:
Devices, Monitoring, Endocrinology, Personnel[Sensors for Medicine and Science, implanted continuous glucose monitor]
Abraxis BioScience Confirms Plan to Spin-off Abraxis Health in 2010 and Announces Management Structure
HSMN NewsFeed,
28 Jan 2010:
Biopharmaceuticals, Personnel[Abraxis BioScience, Abraxis Health]
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
HSMN NewsFeed,
25 Jan 2010:
Biopharmaceuticals, Oncology[Bristol-Myers Squibb, Centocor Ortho Biotech, NCCN, Taxol, Doxil, ovarian cancer]
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
HSMN NewsFeed,
23 Dec 2009:
Biopharmaceuticals, Cardiology, Licensing[Eli Lilly, Kowa Pharmaceuticals, LIVALO, pitavastatin, hyperlipidemia]
Ligand Announces Positive Regulatory Opinion in Europe for Revolade for Chronic Immune Thrombocytopenic Purpura
HSMN NewsFeed,
18 Dec 2009:
Biopharmaceuticals, Regulatory[Ligand Pharmaceuticals, GlaxoSmithKline, Revolade, eltrombopag, Promacta]
Dean Mitchell Appointed to Talecris Board of Directors
HSMN NewsFeed,
17 Dec 2009:
Biopharmaceuticals, Personnel[Talecris Biotherapeutics]
Bristol-Myers Squibb Announces Appointment of Charles Bancroft as Acting Chief Financial Officer
HSMN NewsFeed,
14 Dec 2009:
Biopharmaceuticals, Personnel[Bristol-Myers Squibb]
Tranzyme Pharma Enters Into Strategic Drug Discovery Collaboration with Bristol-Myers Squibb
HSMN NewsFeed,
8 Dec 2009:
Biopharmaceuticals[Tranzyme Pharma, Bristol-Myers Squibb, Macrocyclic Template Chemistry]
XOMA Appoints Jim Neal Vice President of Business Development
HSMN NewsFeed,
17 Nov 2009:
Biopharmaceuticals, Personnel[XOMA]
Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic
HSMN NewsFeed,
10 Nov 2009:
Biopharmaceuticals[Bristol-Myers Squibb, Alder Biopharmaceuticals, ALD518, rheumatoid arthritis]
NeurogesX Expands Commercial Operations Leadership Team
HSMN NewsFeed,
5 Nov 2009:
Biopharmaceuticals, Personnel[NeurogesX, Qutenza, capsaicin]
InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of Pirfenidone
HSMN NewsFeed,
5 Nov 2009:
Biopharmaceuticals, Personnel[InterMune, pirfenidone]
Ligand to Acquire Metabasis for Cash and Contingent Value Rights
HSMN NewsFeed,
27 Oct 2009:
Biopharmaceuticals, Mergers & Acquisitions[Ligand Pharmaceuticals, Metabasis]
New Data Describe Safety of Subcutaneous Administration of ORENCIA(R) (abatacept) For Patients with Moderate to Severe Rheumatoid Arthritis
HSMN NewsFeed,
20 Oct 2009:
Biopharmaceuticals[Bristol-Myers Squibb, ORENCIA, abatacept, rheumatoid arthritis]
Endocyte Officials Announce Close of $26 Million Equity Financing
HSMN NewsFeed,
16 Oct 2009:
Biopharmaceuticals, Venture Capital[Endocyte]
Seattle Genetics Names Head of Commercial and Announces Management Promotion
HSMN NewsFeed,
13 Oct 2009:
Biopharmaceuticals, Personnel[Seattle Genetics]
Data Presented from Two Phase 3 ERBITUX(R) Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress
HSMN NewsFeed,
23 Sep 2009:
Biopharmaceuticals, Oncology[Bristol-Myers Squibb, CRYSTAL study, ERBITUX, cetuximab, colorectal cancer]
AVEO Pharmaceuticals Appoints William J. Slichenmyer, M.D., Sc.M., as Chief Medical Officer and Robert C. Young, M.D., to Board of Directors
HSMN NewsFeed,
16 Sep 2009:
Biopharmaceuticals, Oncology, Personnel[AVEO Pharmaceuticals]
Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
HSMN NewsFeed,
4 Sep 2009:
Biopharmaceuticals, Personnel[Rib-X Pharmaceuticals]
New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of Plavix(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
HSMN NewsFeed,
30 Aug 2009:
Biopharmaceuticals, Interventional Cardiology[Bristol-Myers Squibb, sanofi-aventis, Plavix, clopidogrel]
Updated ORENCIA(R) (abatacept) Labeling Includes Data to Support Earlier Use in Adult Patients with Moderate to Severe Rheumatoid Arthritis
HSMN NewsFeed,
26 Aug 2009:
Biopharmaceuticals[Bristol-Myers Squibb, ORENCIA, abatacept, rheumatoid arthritis]
Adamas Pharmaceuticals Expands Management Team; Names Michael D. Coffee and Amy K. Patick to Executive Positions
HSMN NewsFeed,
25 Aug 2009:
Biopharmaceuticals, Personnel[Adamas Pharmaceuticals]
Symphogen Appoints Adriann Sax Chief Business Officer
HSMN NewsFeed,
17 Aug 2009:
Biopharmaceuticals, Personnel[Symphogen]
XDx Completes $14.4 Million Series G Financing
HSMN NewsFeed,
5 Aug 2009:
Diagnostics, Venture Capital[XDx, molecular diagnostics, personalized medicine]
Bristol-Myers Squibb Begins Tender Offer to Acquire Medarex, Inc.
HSMN NewsFeed,
28 Jul 2009:
Biopharmaceuticals, Mergers & Acquisitions[Bristol-Myers Squibb, Medarex]
ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX(R) (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer
HSMN NewsFeed,
20 Jul 2009:
Biopharmaceuticals, Oncology, FDA[Bristol-Myers Squibb, ImClone Systems, Eli Lilly, ERBITUX, cetuximab, mCRC]
I-Therapeutix, Inc. Closes $15 Million Financing
HSMN NewsFeed,
19 Jun 2009:
Devices, Ophthalmology, Venture Capital[I-Therapeutix, I-ZIP , Ocular Bandage]
ZymoGenetics Appoints Eleanor L. Ramos, M.D. Senior Vice President and Chief Medical Officer
HSMN NewsFeed,
10 Jun 2009:
Biopharmaceuticals, Personnel[ZymoGenetics]
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
HSMN NewsFeed,
1 Jun 2009:
Biopharmaceuticals, Oncology[Merck Serono, Erbitux, cetuximab, mCRC]
New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
HSMN NewsFeed,
29 May 2009:
Biopharmaceuticals, Oncology[Wyeth Pharmaceuticals, Wyeth, neratinib, trastuzumab, Herceptin, HER-2]
FDA Grants Full Approval for SPRYCEL (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec*
HSMN NewsFeed,
26 May 2009:
Biopharmaceuticals, Oncology[Bristol-Myers Squibb, SPRYCEL, dasatinib, chronic myeloid leukemia]
Avila Therapeutics Appoints Katrine S. Bosley as Company's First CEO
HSMN NewsFeed,
15 May 2009:
Biopharmaceuticals, Personnel[Avila Therapeutics]
Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
HSMN NewsFeed,
14 May 2009:
Biopharmaceuticals, FDA[Cadence Pharmaceuticals, Acetavance, intravenous acetaminophen]
CytRx Appoints Jaisim Shah Chief Business Officer and Senior Vice President of Business Development
HSMN NewsFeed,
5 May 2009:
Biopharmaceuticals, Personnel[CytRx]
Ligand Announces Approval in Europe of CONBRIZA for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
HSMN NewsFeed,
27 Apr 2009:
Biopharmaceuticals, Regulatory[Ligand Pharmaceuticals, Wyeth, CONBRIZA, bazedoxifene, osteoporosis]
U.S. Food and Drug Administration Extends Review Timeline for ONGLYZA (saxagliptin) New Drug Application
HSMN NewsFeed,
23 Apr 2009:
Biopharmaceuticals, Endocrinology, FDA[Bristol-Myers Squibb, AstraZenec, ONGLYZA, saxagliptin, diabetes]
Lilly Names Susan Mahony Senior Vice President of Human Resources
HSMN NewsFeed,
17 Apr 2009:
Biopharmaceuticals, Personnel[Eli Lilly]
ARIAD Appoints Former Bristol-Myers Squibb Senior Executive as New Independent Member of Its Board of Directors
HSMN NewsFeed,
6 Apr 2009:
Biopharmaceuticals, Personnel[ARIAD Pharmaceuticals]
FABLYN Approved in Europe for the Treatment of Osteoporosis
HSMN NewsFeed,
24 Mar 2009:
Biopharmaceuticals, Regulatory[Ligand Pharmaceuticals, Pfizer, FABLYN, lasofoxifene, osteoporosis]
BG Medicine: Peter Gardiner Appointed Vice President, Medical Affairs and Senior Medical Officer
HSMN NewsFeed,
19 Mar 2009:
Diagnostics, Personnel[BG Medicine]
Bristol-Myers Squibb Announces Organizational Changes; Names Four to Company's Executive Committee
HSMN NewsFeed,
3 Mar 2009:
Biopharmaceuticals, Personnel[Bristol-Myers Squibb]
Bristol-Myers Squibb Names Andreotti President and Chief Operating Officer
HSMN NewsFeed,
3 Mar 2009:
Biopharmaceuticals, Personnel[Bristol Myers Squibb]
ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX(R) in U.S.
HSMN NewsFeed,
2 Mar 2009:
Biopharmaceuticals, Oncology, FDA[Bristol-Myers Squibb, ImClone Systems, ERBITUX, cetuximab, head and neck cancer]
Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
HSMN NewsFeed,
2 Mar 2009:
Biopharmaceuticals, Personnel[Pearl Therapeutics]
Sopherion Therapeutics Announces Appointment of New Senior Executive Vice President for Clinical Affairs
HSMN NewsFeed,
24 Feb 2009:
Biopharmaceuticals, Personnel[Sopherion Therapeutics]
Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer
HSMN NewsFeed,
12 Feb 2009:
Biopharmaceuticals, Personnel[Otsuka America Pharmaceutical, Otsuka Pharmaceutical]
FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers
HSMN NewsFeed,
10 Feb 2009:
Biopharmaceuticals, Oncology, FDA[Nerviano Medical Sciences, Cdc7]
ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX(R)
HSMN NewsFeed,
23 Jan 2009:
Biopharmaceuticals, Oncology, FDA[Bristol-Myers Squibb, ImClone Systems, Eli Lilly, ERBITUX, cetuximab, NSCLC]
Howard Feldman Joins Bristol-Myers Squibb as Vice President and Therapeutic Area Head, Global Clinical Research, Neuroscience
HSMN NewsFeed,
8 Jan 2009:
Biopharmaceuticals, Personnel[Bristol-Myers Squibb]
ARIAD Expands Management Team with Executive Appointments in Regulatory Affairs, Manufacturing and Information Technology
HSMN NewsFeed,
6 Jan 2009:
Biopharmaceuticals, Personnel[ARIAD Pharmaceuticals]
Mylan's Matrix Receives Final FDA Approval for the Generic Version of the Antiretroviral Zerit(R) Capsules
HSMN NewsFeed,
30 Dec 2008:
Biopharmaceuticals, Generics, FDA, HIV/AIDS[Mylan, Matrix Laboratories Limited, Stavudine, Bristol-Myers Squibb, Zerit]
Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs
HSMN NewsFeed,
12 Dec 2008:
Biopharmaceuticals, Oncology[Bristol-Myers Squibb, Exelixis, XL184, XL281]
ERBITUXŽ Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted to U.S. Food and Drug Administration
HSMN NewsFeed,
8 Dec 2008:
Biopharmaceuticals, Oncology[Bristol-Myers Squibb, Eli Lilly, ImClone Systems, ERBITUX, cetuximab, NSCLC]
Avila Therapeutics Appoints Daniel S. Lynch as Executive Chairman
HSMN NewsFeed,
5 Dec 2008:
Biopharmaceuticals, Personnel[Avila Therapeutics]
Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
HSMN NewsFeed,
2 Dec 2008:
Biopharmaceuticals, Personnel[Regado Biosciences]
NCCN Receives $1.5 Million Grant to Research Targeted Therapy in Bladder Cancer
HSMN NewsFeed,
24 Nov 2008:
Biopharmaceuticals, Oncology[NCCN, Bristol-Myers Squibb, ImClone Systems, cetuximab, ERBITUX, bladder cancer]
NCCN Updates Guidelines for Colorectal Cancer
HSMN NewsFeed,
3 Nov 2008:
Biopharmaceuticals, Oncology[National Comprehensive Cancer Network, KRAS, mCRC]
ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
HSMN NewsFeed,
29 Oct 2008:
Biopharmaceuticals, Oncology[ImClone Systems, Bristol-Myers Squibb, ERBITUX, cetuximab, mCRC]
Hospitals, Healthcare Providers to Save with Premier Agreement for Cardiac Ultrasound Contrast Media
HSMN NewsFeed,
23 Oct 2008:
Biopharmaceuticals, Radiology, Group Purchasing[Premier Purchasing, Lantheus Medical Imaging]
Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Response to ERBITUX(R) Treatment
HSMN NewsFeed,
22 Oct 2008:
Biopharmaceuticals, Oncology[Bristol-Myers Squibb, ImClone Systems, K-ras, ERBITUX, cetuximab, mCRC]
Abraxis BioScience and Specialised Therapeutics Australia Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in Australia
HSMN NewsFeed,
16 Oct 2008:
Biopharmaceuticals, Oncology, Regulatory[Abraxis BioScience, ABRAXANE, paclitaxel, metastatic breast cancer]
Excaliard Pharmaceuticals Appoints Lincoln Krochmal, MD, President & Chief Executive Officer and Jeffrey Jenson, Head of Clinical Operations.
HSMN NewsFeed,
10 Oct 2008:
Biopharmaceuticals, Dermatology, Personnel[Excaliard Pharmaceuticals]
ImClone Announces Merger Agreement with Eli Lilly at $70 Per Share
HSMN NewsFeed,
6 Oct 2008:
Biopharmaceuticals, Mergers & Acquisitions[ImClone Systems, Eli Lilly]
PDL BioPharma Names Faheem Hasnain President and Chief Executive Officer
HSMN NewsFeed,
25 Sep 2008:
Biopharmaceuticals, Personnel[PDL BioPharma]
Bristol-Myers Squibb to Commence Cash Tender Offer for ImClone Systems at $62.00 per share
HSMN NewsFeed,
22 Sep 2008:
Biopharmaceuticals, Mergers & Acquisitions[Bristol-Myers Squibb, ImClone Systems]
ERBITUX(R) Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer
HSMN NewsFeed,
19 Sep 2008:
Biopharmaceuticals, Oncology[ImClone Systems, ERBITUX, cetuximab, metastatic colorectal cancer]
Christine A. Poon Plans Retirement from Johnson & Johnson in Early 2009
HSMN NewsFeed,
12 Sep 2008:
Biopharmaceuticals, Personnel[Johnson & Johnson]
Bristol-Myers Squibb Submits Letter to ImClone Board of Directors
HSMN NewsFeed,
11 Sep 2008:
Biopharmaceuticals, Mergers & Acquisitions[Bristol-Myers Squibb, ImClone Systems]
ImClone Systems Issues Statement
HSMN NewsFeed,
10 Sep 2008:
Biopharmaceuticals, Mergers & Acquisitions[ImClone Systems, Bristol-Myers Squibb]
Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO
HSMN NewsFeed,
8 Sep 2008:
Biopharmaceuticals, Personnel[Zosano Pharma]
Inverness Medical Launches Portable Blood Testing Monitor to Warn Patients and Their Physicians of Potential Blood Clots
HSMN NewsFeed,
5 Sep 2008:
Diagnostics[Inverness Medical, INRatio2, PT/INR Monitoring, prothrombin time]
Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
HSMN NewsFeed,
3 Sep 2008:
Biopharmaceuticals, Personnel[Wyeth]
ImClone Submits Supplemental Biologics License Application for ERBITUX(R) in First-Line Head and Neck Cancer
HSMN NewsFeed,
3 Sep 2008:
Biopharmaceuticals, Oncology[ImClone Systems, ERBITUX, cetuximab, head and neck cancer]
New Data is Presented on Investigational Oral Anticoagulant Apixaban in Acute Coronary Syndrome Patients
HSMN NewsFeed,
2 Sep 2008:
Biopharmaceuticals, Cardiology[Pfizer, Bristol-Myers Squibb, apixaban, acute coronary syndrome]
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
HSMN NewsFeed,
29 Aug 2008:
Biopharmaceuticals, Oncology[ImClone Systems, ERBITUX, cetuximab, non-small cell lung cancer]
Bristol-Myers Squibb Welcomes NICE Guidance Recommending Baraclude(R) (entecavir) as a Treatment Option for Chronic Hepatitis B
HSMN NewsFeed,
29 Aug 2008:
Biopharmaceuticals[Bristol-Myers Squibb, Baraclude, entecavir, hepatitis B]
Biovail Appoints Dr. Neil M. Sussman Vice-President, Neurologic & Psychiatric Development
HSMN NewsFeed,
20 Aug 2008:
Biopharmaceuticals, Personnel[Biovail]
Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development
HSMN NewsFeed,
19 Aug 2008:
Biopharmaceuticals, Drug Delivery, Personnel[ Emisphere Technologies]
ISENTRESS(R) (raltegravir), Merck's First in Class Integrase Inhibitor, Reduced HIV Viral Load and Increased CD4 Cell Counts Through 96 Weeks in Treatment-Naive HIV-Infected Patients When Taken With Other Anti-HIV Medicines
HSMN NewsFeed,
5 Aug 2008:
Biopharmaceuticals, HIV/AIDS[Merck, ISENTRESS]
CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender
HSMN NewsFeed,
5 Aug 2008:
Biopharmaceuticals, HIV/AIDS[Bristol-Myers Squibb, CASTLE study, REYATAZ, atazanavir]
Pharmacopeia Announces Further Reductions to Workforce
HSMN NewsFeed,
5 Aug 2008:
Biopharmaceuticals[Pharmacopeia]
ImClone Systems Issues Statement
HSMN NewsFeed,
4 Aug 2008:
Biopharmaceuticals, Mergers & Acquisitions[ImClone Systems, Bristol-Myers Squibb]
Gilead Sciences and Merck & Co., Inc. Enter Into an Agreement to Register and Distribute HIV Medication Atripla(R) (Efavirenz 600 mg/ Emtricitabine 200 mg/ Tenofovir Disoproxil Fumarate 300 mg) in Twelve Countries
HSMN NewsFeed,
1 Aug 2008:
Biopharmaceuticals, HIV/AIDS, Distribution[Gilead Sciences, Merck, Atripla]
Bristol-Myers Squibb Proposes to Acquire ImClone Systems for $60.00 Per Share in Cash
HSMN NewsFeed,
31 Jul 2008:
Biopharmaceuticals, Mergers & Acquisitions[Bristol-Myers Squibb, ImClone Systems]
Oscient Pharmaceuticals Promotes Mark A. Glickman to Senior Vice President, Sales and Marketing
HSMN NewsFeed,
30 Jul 2008:
Biopharmaceuticals, Personnel[Oscient Pharmaceuticals]
Bristol-Myers Squibb and AstraZeneca Submit New Drug Application in the United States and Marketing Authorization Application in Europe for ONGLYZA(TM) (saxagliptin) for the Treatment of Type 2 Diabetes
HSMN NewsFeed,
23 Jul 2008:
Biopharmaceuticals, FDA, Endocrinology[Bristol-Myers Squibb, AstraZeneca, ONGLYZA, saxagliptin, diabetes]
Bristol-Myers Squibb Names Chief Procurement Officer
HSMN NewsFeed,
21 Jul 2008:
Biopharmaceuticals, Personnel[Bristol-Myers Squibb]
ERBITUX(R) (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer
HSMN NewsFeed,
16 Jul 2008:
Biopharmaceuticals, Oncology, Regulatory[ImClone Systems, ERBITUX, cetuximab, Colorectal Cancer]
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in China
HSMN NewsFeed,
14 Jul 2008:
Biopharmaceuticals, Oncology, Regulatory[Abraxis BioScience, ABRAXANE, Paclitaxel, breast cancer]
Gemin X Pharmaceuticals Appoints Peter R. Dolan to Board of Directors
HSMN NewsFeed,
8 Jul 2008:
Biopharmaceuticals, Personnel[Gemin X Pharmaceuticals]
A.P. Pharma Appoints Ronald J. Prentki as President, Chief Executive Officer and Member of Its Board of Directors
HSMN NewsFeed,
7 Jul 2008:
Biopharmaceuticals, Personnel[A.P. Pharma]
Agios Pharmaceuticals Closes $33 Million Series A Funding
HSMN NewsFeed,
7 Jul 2008:
Biopharmaceuticals, Oncology, Venture Capital[Agios Pharmaceuticals, Third Rock Ventures]
Tobira Therapeutics Inc. Announces Senior Management Team
HSMN NewsFeed,
30 Jun 2008:
Biopharmaceuticals, Personnel[Tobira Therapeutics]
Nordic Capital and Avista Capital Partners Announce Intention to Combine Unomedical with Convatec
HSMN NewsFeed,
27 Jun 2008:
Devices, Wound Care, Mergers & Acquisitions[ConvaTec, Unomedical, Nordic Capital, Avista Capital Partners]
Bristol-Myers Squibb Completes Tender Offer for Kosan Biosciences Incorporated
HSMN NewsFeed,
26 Jun 2008:
Biopharmaceuticals, Mergers & Acquisitions[Bristol-Myers Squibb, Kosan Biosciences]
European Commission Approves REYATAZ(R) (Atazanavir Sulfate 100mg, 150mg, 200mg, 300mg), in Combination With Other Antiretroviral Medicinal Products, for use in Treatment Naďve HIV-1 Infected Adults
HSMN NewsFeed,
24 Jun 2008:
Biopharmaceuticals, HIV/AIDS, Regulatory[Bristol-Myers Squibb, REYATAZ, atazanavir, ritonavir, antiretroviral]
Vertex Pharmaceuticals Announces the Appointment of Freda C. Lewis-Hall, M.D., as Executive Vice President, Medicines Development
HSMN NewsFeed,
18 Jun 2008:
Biopharmaceuticals, Personnel[Vertex Pharmaceuticals]
Three Industry Veterans Join Ascension Orthopedics
HSMN NewsFeed,
13 Jun 2008:
Devices, Orthopaedic, Personnel[Ascension Orthopedics]
ORENCIA(R) (abatacept) Provided an Increasing Degree of Inhibition of Structural Damage Through Three Years in Adults with Moderate to Severe Rheumatoid Arthritis
HSMN NewsFeed,
12 Jun 2008:
Biopharmaceuticals[Bristol-Myers Squibb, AIM study, Abatacept, ORENCIA, rheumatoid arthritis]
Merck Serono Strengthens its Prescription Medicines Portfolio in Latin America
HSMN NewsFeed,
10 Jun 2008:
Biopharmaceuticals, Distribution[Merck Serono, Merck KGaA, Bristol-Myers Squibb]
Lexicon's Drug Candidate for Carcinoid Syndrome Receives Fast Track Status From the FDA
HSMN NewsFeed,
3 Jun 2008:
Biopharmaceuticals[Lexicon Pharmaceuticals, LX1032, carcinoid syndrome, fast track designation]
ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
HSMN NewsFeed,
31 May 2008:
Biopharmaceuticals, Oncology[Bristol-Myers Squibb, ERBITUX, cetuximab, non-small cell lung cancer]
Bristol-Myers Squibb to Acquire Kosan Biosciences
HSMN NewsFeed,
29 May 2008:
Biopharmaceuticals, Mergers & Acquisitions[Bristol-Myers Squibb, Kosan Biosciences]
ARIAD Appoints Former Bristol-Myers Squibb Executive to Lead Corporate Legal and Compliance Functions
HSMN NewsFeed,
28 May 2008:
Biopharmaceuticals, Personnel[ARIAD Pharmaceuticals]
Cantel Medical Appoints New Director
HSMN NewsFeed,
27 May 2008:
Devices, Personnel[Cantel Medical]
Endo Pharmaceuticals Appoints Blaine T. Davis as Vice President, Investor Relations and Corporate Communications
HSMN NewsFeed,
22 May 2008:
Biopharmaceuticals, Personnel[Endo Pharmaceuticals]
Ipsen: Appointment of Gerard Picot as Vice President, Global Regulatory Affairs
HSMN NewsFeed,
22 May 2008:
Biopharmaceuticals, Personnel[Ipsen]
Proteolix Appoints Thomas Kassberg Executive Vice President of Corporate Development
HSMN NewsFeed,
15 May 2008:
Biopharmaceuticals, Personnel[Proteolix, proteasome]
Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke
HSMN NewsFeed,
15 May 2008:
Neurology[REACH Registry, stroke]
Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team
HSMN NewsFeed,
14 May 2008:
Biopharmaceuticals, Personnel[Fate Therapeutics]
ConvaTec Introduces VERSIVA(R) XC(TM) Gelling Foam Dressings to U.S.
HSMN NewsFeed,
14 May 2008:
Devices, Wound Care[ConvaTec, Versiva XC, Gelling Foam Dressings, Hydrofiber]
Bristol-Myers Squibb and KAI Pharmaceuticals Enter Global Alliance to Develop and Commercialize KAI-9803 for Cardiovascular Disease
HSMN NewsFeed,
13 May 2008:
Biopharmaceuticals[Bristol-Myers Squibb, KAI Pharmaceuticals, KAI-9803]
Nordic Capital Fund VII and Avista Capital Partners Agree to Acquire ConvaTec Business for approximately $4.1 Billion
HSMN NewsFeed,
2 May 2008:
Biopharmaceuticals, Devices, Wound Care[Bristol-Myers Squibb, ConvaTec]
ConvaTec Upgrades Flexi-Seal(R) Fecal Management System to Increase Ease of Use
HSMN NewsFeed,
2 May 2008:
Devices, Wound Care[ConvaTec, Flexi-Seal, Fecal Management System]
HeartWare Appoints David R. Hathaway, M.D. Chief Medical Officer
HSMN NewsFeed,
28 Apr 2008:
Devices, Personnel[HeartWare]
Ceregene Announces Two Key Additions to Leadership Team
HSMN NewsFeed,
23 Apr 2008:
Biopharmaceuticals, Personnel[Ceregene]
Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
HSMN NewsFeed,
17 Apr 2008:
Biopharmaceuticals, Personnel[Eisai]
Phytomedics Inc. Appoints Dr. Laurie Smaldone Alsup, MD., as President and Chief Executive Officer
HSMN NewsFeed,
15 Apr 2008:
Biopharmaceuticals, Personnel[Phytomedics]
Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc.
HSMN NewsFeed,
10 Apr 2008:
Biopharmaceuticals, Personnel[Pharmacopeia]
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
HSMN NewsFeed,
9 Apr 2008:
Biopharmaceuticals, Oncology, Regulatory[Abraxis BioScience, ABRAXANE, paclitaxel, breast cancer]
ADVENTRX Appoints Vice President of Manufacturing
HSMN NewsFeed,
9 Apr 2008:
Biopharmaceuticals, Personnel[ADVENTRX Pharmaceuticals]
U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
HSMN NewsFeed,
8 Apr 2008:
Biopharmaceuticals, FDA[Bristol-Myers Squibb, ORENCIA, abatacept, juvenile idiopathic arthritis]
Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
HSMN NewsFeed,
8 Apr 2008:
Biopharmaceuticals, Litigation[Repligen, Bristol-Myers Squibb, Orencia]
Bristol-Myers Squibb and Otsuka Receive European Marketing Authorisation for ABILIFY(R) in the Treatment and Prevention of Moderate to Severe Manic Episodes in Bipolar I Disorder
HSMN NewsFeed,
8 Apr 2008:
Biopharmaceuticals, Regulatory[Bristol-Myers Squibb, Otsuka Pharmaceutical, ABILIFY, aripiprazole]
Medarex Announces Ipilimumab Program Continues to Move Forward
HSMN NewsFeed,
3 Apr 2008:
Biopharmaceuticals, Oncology[Medarex, Pfizer, tremelimumab, ipilimumab]
Discovery Labs Adds Two Executives to Its Management Team
HSMN NewsFeed,
27 Mar 2008:
Biopharmaceuticals, Personnel[Discovery Laboratories]
BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
HSMN NewsFeed,
24 Mar 2008:
Biopharmaceuticals[Bristol-Myers Squibb, BARACLUDE, entecavir, hepatitis B]
XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
HSMN NewsFeed,
20 Mar 2008:
Biopharmaceuticals, Licensing[XTL Biopharmaceuticals, Presidio Pharmaceuticals, Hepatitis C, NS5A]
Icagen Announces Senior Management Promotions
HSMN NewsFeed,
19 Mar 2008:
Biopharmaceuticals, Personnel[Icagen]
Worldwide Leader in Diagnostic Medicine is Launched as Lantheus Medical Imaging
HSMN NewsFeed,
18 Mar 2008:
Biopharmaceutials, Radiology[Lantheus Medical Imaging, Bristol-Myers Squibb Medical Imaging, imaging]
Abraxis Bioscience Announces Filing of Marketing Application in Japan for ABRAXANE in the Treatment of Breast Cancer
HSMN NewsFeed,
17 Mar 2008:
Biopharmaceuticals, Oncology, Regulatory[Abraxis BioScience, ABRAXANE, paclitaxel, breast cancer]
Barr Receives Approval for Generic Taxol(R) Injection USP, 6mg/mL
HSMN NewsFeed,
12 Mar 2008:
Biopharmaceuticals, Generics, Oncology, FDA[Barr Pharmaceuticals, PLIVA, Bristol-Myers Squibb, Taxol, paclitaxel]
Vitae Pharmaceuticals Appoints Richard Gregg, M.D. as Chief Scientific Officer
HSMN NewsFeed,
5 Mar 2008:
Biopharmaceuticals, Personnel[Vitae Pharmaceuticals]
Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer
HSMN NewsFeed,
5 Mar 2008:
Biopharmaceuticals, Personnel[Bristol-Myers Squibb]
New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)
HSMN NewsFeed,
5 Mar 2008:
Biopharmaceuticals, Cardiology, Regulatory[sanofi-aventis, Bristol-Myers Squibb, Plavix, Acute Coronary Syndrome]
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
HSMN NewsFeed,
29 Feb 2008:
Biopharmaceuticals, FDA[Otsuka Pharmaceutical, ABILIFY, aripiprazole, bipolar disorder]
Tercica Announces Changes to Its Board of Directors and Management Team
HSMN NewsFeed,
29 Feb 2008:
Biopharmaceuticals, Personnel[Tercica]
Pharmacopeia Announces Management Team Changes
HSMN NewsFeed,
28 Feb 2008:
Biopharmaceuticals, Personnel[Pharmacopeia]
Covidien Announces Tentative FDA Approval for Its Generic Myocardial Perfusion Imaging Kit
HSMN NewsFeed,
27 Feb 2008:
Biopharmaceuticals, Generics, FDA[Covidien, Technetium, Tc 99m, Sestamibi, Cardiolite1, Bristol-Myers Squibb]
Onyx Pharmaceuticals Names N. Anthony Coles, M.D. as President, Chief Executive Officer and Member of its Board of Directors
HSMN NewsFeed,
26 Feb 2008:
Biopharmaceuticals, Personnel[Onyx Pharmaceuticals]
Novo Nordisk Consolidates U.S. Diabetes Sales Leadership Under Single Vice President
HSMN NewsFeed,
19 Feb 2008:
Biopharmaceuticals, Personnel[Novo Nordisk, Pamela Harris]
BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
HSMN NewsFeed,
14 Feb 2008:
Biopharmaceuticals, Personnel[BiPar Sciences]
Bristol-Myers Squibb Board Elects James M. Cornelius Chairman of the Board
HSMN NewsFeed,
12 Feb 2008:
Biopharmaceuticals, Personnel[Bristol-Myers Squibb]
Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer
HSMN NewsFeed,
11 Feb 2008:
Biopharmaceuticals, Personnel[Regulus Therapeutics]
APP Pharmaceuticals Receives FDA Approval for Bleomycin Sulfate for Injection, USP
HSMN NewsFeed,
8 Feb 2008:
Biopharmaceuticals, Generics, FDA[APP Pharmaceuticals, Bleomycin, Blenoxane, Bristol-Myers Squibb]
MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
HSMN NewsFeed,
7 Feb 2008:
Biopharmaceuticals, Personnel[MedImmune]
Abraxis Bioscience Establishes Global Leadership Team
HSMN NewsFeed,
7 Feb 2008:
Biopharmaceuticals, Personnel[Abraxis BioScience]
CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
HSMN NewsFeed,
6 Feb 2008:
Biopharmaceuticals, HIV/AIDS[Bristol-Myers Squibb, CASTLE study, REYATAZ, atazanavir, ritonavir]
Neurogen Corporation Announces Appointment of Stephen R. Davis as President & CEO
HSMN NewsFeed,
4 Feb 2008:
Biopharmaceuticals, Personnel[Neurogen]
PolyMedix Appoints Brian Anderson to Board of Directors
HSMN NewsFeed,
29 Jan 2008:
Biopharmaceuticals, Personnel[PolyMedix]
Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
HSMN NewsFeed,
28 Jan 2008:
Biopharmaceuticals, Personnel[Lentigen Corp]
Gloucester Pharmaceuticals Announces New Senior Management Team
HSMN NewsFeed,
28 Jan 2008:
Biopharmaceuticals, Personnel[Gloucester Pharmaceuticals]
Abraxis Receives Approval from EU Commission to Market ABRAXANE for Metastatic Breast Cancer in Europe
HSMN NewsFeed,
22 Jan 2008:
Biopharmaceuticals, Oncology, Regulatory[Abraxis BioScience, ABRAXANE, paclitaxel, breast cancer]
Exelixis and Bristol-Myers Squibb to Co-Develop XL139, an Inhibitor of the Hedgehog Pathway
HSMN NewsFeed,
22 Jan 2008:
Biopharmaceuticals, Oncology[Exelixis, Bristol-Myers Squibb, XL139, hedgehog pathway]
GSK Does Not Option XL784 for Further Development
HSMN NewsFeed,
18 Jan 2008:
Biopharmaceuticals, Licensing[Exelixis, GlaxoSmithKline, XL784, metalloprotease, diabetic nephropathy]
VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
HSMN NewsFeed,
16 Jan 2008:
Biopharmaceuticals, Personnel[VIA Pharmaceuticals]
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
HSMN NewsFeed,
14 Jan 2008:
Biopharmaceuticals, Endocrinology, Generics, FDA[Caraco Pharmaceutical, Glipizide, Metformin, Metaglip, Bristol-Myers Squibb]
Teva Announces Departure of North American CEO William S. Marth to Become CEO of Teva North America
HSMN NewsFeed,
10 Jan 2008:
Biopharmaceuticals, Personnel[Teva Pharmaceutical]
Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
HSMN NewsFeed,
8 Jan 2008:
Devices, Radiology, Acquisitions[Bristol-Myers Squibb, Bristol-Myers Squibb Medical Imaging]
Exelixis Announces Senior Management Promotions
HSMN NewsFeed,
4 Jan 2008:
Biopharmaceuticals, Personnel[Exelixis]
Curis, Inc. Announces Appointment of Stephen K. Carter, M.D. to its Board of Directors
HSMN NewsFeed,
19 Dec 2007:
Biopharmaceuticals, Personnel[Curis]
FDA Approves Celltrion to Manufacture ORENCIA(R) (abatacept)
HSMN NewsFeed,
18 Dec 2007:
Biopharmaceuticals, FDA[Celltrion, Bristol-Myers Squibb, ORENCIA, abatacept, rheumatoid arthritis]
Avista Capital Partners Agrees to Acquire Bristol-Myers Squibb Medical Imaging for Approximately $525 Million
HSMN NewsFeed,
17 Dec 2007:
Biopharmaceuticals, Radiology, Acquisitions[Bristol-Myers Squibb, Avista Capital Partners, Medical Imaging]
Heartscape Technologies Appoints Former Medtronic Executive to Role as Chairman and Independent Director
HSMN NewsFeed,
11 Dec 2007:
Devices, Personnel[Heartscape Technologies]
Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
HSMN NewsFeed,
11 Dec 2007:
Biopharmaceuticals, HIV/AIDS[Gilead Sciences, Bristol-Myers Squibb, ATRIPLA]
Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community
HSMN NewsFeed,
5 Dec 2007:
Biopharmaceuticals[Bristol-Myers Squibb]
Ray Elliott to Retire as Chairman of Zimmer Holdings; John McGoldrick to Serve as Non-Executive Chairman
HSMN NewsFeed,
27 Nov 2007:
Devices, Orthopaedic, Personnel[Zimmer Holdings]
ARIAD Expands Leadership Team with Three New Appointments
HSMN NewsFeed,
27 Nov 2007:
Biopharmaceuticals, Personnel[ARIAD Pharmaceuticals, Matthew E. Ros]
Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
HSMN NewsFeed,
23 Nov 2007:
Biopharmaceuticals, Oncology, Licensing[Bristol-Myers Squibb, Pierre Fabre Medicament, vinflunine, bladder cancer]
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
HSMN NewsFeed,
20 Nov 2007:
Biopharmaceuticals, FDA[Bristol-Myers Squibb, Otsuka Pharmaceutical, ABILIFY, aripiprazole, depression]
Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve BP Goals
HSMN NewsFeed,
19 Nov 2007:
Biopharmaceuticals, Cardiology, FDA[Bristol-Myers Squibb, AVALIDE, irbesartan, HCTZ, hypertension]
Significant Changes in Store for Growing HIV Market
HSMN NewsFeed,
15 Nov 2007:
Biopharmaceuticals, HIV/AIDS[GlaxoSmithKline, Gilead, Bristol-Myers Squibb, Tibotec, Johnson & Johnson]
NCCN Receives Major Grant for Anti-Cancer Drug Study
HSMN NewsFeed,
15 Nov 2007:
Biopharmaceuticals, Oncology[Bristol-Myers Squibb, ImClone Systems, NCCN, ERBITUX, cetuximab]
ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration
HSMN NewsFeed,
15 Nov 2007:
Biopharmaceuticals, FDA[Bristol-Myers Squibb, Otsuka Pharmaceutical, ABILIFY, aripiprazole]
New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
HSMN NewsFeed,
14 Nov 2007:
Biopharmaceuticals, Oncology[ImClone Systems, ERBITUX, cetuximab, metastatic colorectal cancer]
Ambit Biosciences Raises Over $49 Million in Series D Financing
HSMN NewsFeed,
14 Nov 2007:
Biopharmaceuticals, Venture Capital[Ambit Biosciences]
Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
HSMN NewsFeed,
12 Nov 2007:
Biopharmaceuticals, FDA[Lexicon Pharmaceuticals, LX2931, rheumatoid arthritis]
Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
HSMN NewsFeed,
9 Nov 2007:
Biopharmaceuticals[Bristol-Myers Squibb, ORENCIA, abatacept, rheumatoid arthritis]
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
HSMN NewsFeed,
8 Nov 2007:
Biopharmaceuticals, FDA, Oncology[Bristol-Myers Squibb, SPRYCEL, Dasatinib, CML]
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia
HSMN NewsFeed,
6 Nov 2007:
Biopharmaceuticals, FDA[Otsuka Pharmaceutical, Bristol-Myers Squibb, ABILIFY, aripiprazole]
Ninety-one Percent of BARACLUDE(R) (entecavir) Treated Patients in a Four-Year Cohort Demonstrated Virologic Suppression to Undetectable Levels
HSMN NewsFeed,
2 Nov 2007:
Biopharmaceuticals[Bristol-Myers Squibb, BARACLUDE, entecavir, hepatitis B]
Amira Pharmaceuticals Appoints First Vice President of Development
HSMN NewsFeed,
1 Nov 2007:
Biopharmaceuticals, Personnel[Amira Pharmaceuticals, eicosanoid]
NPS Pharmaceuticals Names Douglas N. Dobak Vice President of Regulatory Affairs and Drug Safety
HSMN NewsFeed,
30 Oct 2007:
Biopharmaceuticals, Personnel[NPS Pharmaceuticals]
Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients
HSMN NewsFeed,
29 Oct 2007:
Biopharmaceuticals, HIV/AIDS[Gilead Sciences, Truvada, emtricitabine, tenofovir, SWEET Study]
NCCN Updates Multiple Myeloma Guidelines
HSMN NewsFeed,
23 Oct 2007:
Biopharmaceuticals, Oncology[bortezomib, Velcade, doxorubicin, Cytoxan, etoposide, Multiple Myeloma]
Abraxis BioScience Receives a Positive Opinion in Europe from the CHMP for the Approval of ABRAXANE for the Treatment of Metastatic Breast Cancer
HSMN NewsFeed,
18 Oct 2007:
Biopharmaceuticals, Oncology, Regulatory[Abraxis BioScience, ABRAXANE, paclitaxel, breast cancer]
European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
HSMN NewsFeed,
18 Oct 2007:
Biopharmaceuticals, HIV/AIDS, Regulatory[Gilead Sciences, Bristol-Myers Squibb, Merck, ATRIPLA, efavirenz, tenofovir]
Abraxis BioScience and Biocon Limited Announce Approval of ABRAXANE in India for the Treatment of Breast Cancer
HSMN NewsFeed,
18 Oct 2007:
Biopharmaceuticals, Oncology, Regulatory[Abraxis BioScience, Biocon Limited, ABRAXANE, paclitaxel, breast cancer]
Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
HSMN NewsFeed,
17 Oct 2007:
Biopharmaceuticals, Regulatory, HIV/AIDS[Gilead Sciences, Bristol-Myers Squibb, ATRIPLA, antiretroviral]
ImClone and Bristol-Myers Squibb Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
HSMN NewsFeed,
17 Oct 2007:
Biopharmaceuticals, Oncology[ImClone Systems, Bristol-Myers Squibb, Merck KGaA, ERBITUX, cetuximab]
FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
HSMN NewsFeed,
16 Oct 2007:
Biopharmaceuticals, Oncology, FDA[Bristol-Myers Squibb, IXEMPRA, ixabepilone, breast cancer]
Abraxis Bioscience Reaches Agreement with the FDA Following Special Protocol Assessment for Phase III Trial of ABRAXANE in Non-Small Cell Lung Cancer
HSMN NewsFeed,
15 Oct 2007:
Biopharmaceuticals, Oncology, FDA[Abraxis BioScience, ABRAXANE, paclitaxel, non-small cell lung cancer]
Pharmacopeia Acquires Selective Androgen Receptor Modulator ('SARM') Program from Bristol-Myers Squibb
HSMN NewsFeed,
15 Oct 2007:
Biopharmaceuticals, Licensing[Pharmacopeia, Bristol-Myers Squibb, selective androgen receptor modulator]
Indigo Pharmaceuticals Appoints Dennis R. Cryer as Chief Medical Officer
HSMN NewsFeed,
9 Oct 2007:
Biopharmaceuticals, Personnel[Indigo Pharmaceuticals]
Acusphere Appoints New Chief Financial Officer
HSMN NewsFeed,
3 Oct 2007:
Biopharmaceuticals, Personnel[Acusphere]
Cellectar Expands Clinical Management Team
HSMN NewsFeed,
3 Oct 2007:
Biopharmaceuticals, Oncology, Personnel[Cellectar, radiotherapy, radiopharmaceutical]
Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
HSMN NewsFeed,
2 Oct 2007:
Biopharmaceuticals, Oncology, FDA[ImClone Systems, Bristol-Myers Squibb, ERBITUX, Cetuximab, colorectal cancer]
Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
HSMN NewsFeed,
28 Sep 2007:
Biopharmaceuticals[Bristol-Myers Squibb]
Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing
HSMN NewsFeed,
27 Sep 2007:
Biopharmaceuticals, Personnel[Bristol-Myers Squibb]
FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
HSMN NewsFeed,
27 Sep 2007:
Biopharmaceuticals, Cardiology, FDA[Bristol-Myers Squibb, Acute Coronary Syndrome, PLAVIX, clopidogrel]
Lexicon Appoints Judith Swain, M.D. to Board of Directors
HSMN NewsFeed,
25 Sep 2007:
Biopharmaceuticals, Personnel[Lexicon Pharmaceuticals]
Bristol-Myers Squibb to Acquire Adnexus Therapeutics
HSMN NewsFeed,
24 Sep 2007:
Biopharmaceuticals, Mergers & Acquisitions[Bristol-Myers Squibb, Adnexus Therapeutics, Adnectins]
Presidio Pharmaceuticals Adds Industry Veteran Dr. Richard Colonno as Chief Scientific Officer
HSMN NewsFeed,
18 Sep 2007:
Biopharmaceuticals, Personnel[Presidio Pharmaceuticals]
FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
HSMN NewsFeed,
17 Sep 2007:
Biopharmaceuticals, Urology, FDA[Ortho-McNeil, LEVAQUIN, levofloxacin, urinary tract infection]
Micromet Appoints Mark Reisenauer as Senior Vice President and Chief Commercial Officer
HSMN NewsFeed,
12 Sep 2007:
Biopharmaceuticals, Personnel[Micromet]
Pharmacopeia Announces Senior Additions to Management Team
HSMN NewsFeed,
11 Sep 2007:
Biopharmaceuticals, Personnel[Pharmacopeia]
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
HSMN NewsFeed,
11 Sep 2007:
Biopharmaceuticals, Oncology[ImClone Systems, Bristol-Myers Squibb, ERBITUX, Cetuximab, NSCLC]
Aradigm and CyDex Sign Development Collaboration Agreement
HSMN NewsFeed,
6 Sep 2007:
Biopharmaceuticals, Drug Delivery[ Aradigm, CyDex, Captisol, inhalation]
REACH Registry Highlights That Patients With Peripheral Arterial Disease (PAD) Suffer High Rates of Heart Attack, Stroke, Hospitalization, and Death
HSMN NewsFeed,
5 Sep 2007:
Cardiology[REACH Registry, atherothrombosis, peripheral arterial disease]
Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
HSMN NewsFeed,
30 Aug 2007:
Biopharmaceuticals[Cadence Pharmaceuticals, IV acetaminophen]
IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
HSMN NewsFeed,
27 Aug 2007:
Biopharmaceuticals, Personnel[IDM Pharma]
Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
HSMN NewsFeed,
27 Aug 2007:
Biopharmaceuticals[Bristol-Myers Squibb, Pfizer, DGAT-1 inhibitors, DGAT- 1]
Oscient Pharmaceuticals Names Aaron D. Berg Vice President of Marketing and Mark A. Glickman Vice President of Sales
HSMN NewsFeed,
23 Aug 2007:
Biopharmaceuticals, Personnel[Oscient Pharmaceuticals]
GlaxoSmithKline Accelerates Review of Exelixis' XL880
HSMN NewsFeed,
23 Aug 2007:
Biopharmaceuticals[Exelixis, GlaxoSmithKline, XL880]
ConvaTec Launches Moldable Technology(TM), Custom-Fitting Skin Barriers
HSMN NewsFeed,
15 Aug 2007:
Devices, Wound Care[ConvaTec, Moldable Technology, ostomy, skin barrier, SUR-FIT Natura]
TyRx Pharma, Inc., Announces the Hiring of Mark Citron as Vice President, Clinical and Regulatory Affairs
HSMN NewsFeed,
13 Aug 2007:
Biopharmaceuticals, Personnel[TyRx Pharma]
Pacific Beach BioSciences and Dong Wha Pharmaceuticals Sign Exclusive License Agreement to Develop and Commercialize Zabofloxacin (PB-101, DW-224a)
HSMN NewsFeed,
10 Aug 2007:
Biopharmaceuticals, Licensing[Pacific Beach BioSciences, Dong Wha Pharmaceutical, Zabofloxacin]
ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
HSMN NewsFeed,
7 Aug 2007:
Biopharmaceuticals, FDA[Bristol-Myers Squibb, ORENCIA, abatacept, juvenile idiopathic arthritis]
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
HSMN NewsFeed,
6 Aug 2007:
Biopharmaceuticals[Pfizer]
Tobira Therapeutics Inc. Completes $31 Million Series A Financing and Names Management Team
HSMN NewsFeed,
1 Aug 2007:
Biopharmaceuticals, HIV/AIDS, Venture Capital, Personnel[Tobira Therapeutics]
Gene Logic Recruits Pharmaceutical Executive as Senior Vice President of Clinical Development
HSMN NewsFeed,
31 Jul 2007:
Biopharmaceuticals, Personnel[Gene Logic]
Elusys Appoints New Chairman of the Board and a Vice President of Development
HSMN NewsFeed,
30 Jul 2007:
Biopharmaceuticals, Personnel[Elusys Therapeutics]
Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program
HSMN NewsFeed,
27 Jul 2007:
Biopharmaceuticals, Oncology[Bristol-Myers Squibb, ImClone Systems, ERBITUX, Cetuximab]
Spectrum Pharmaceuticals Acquires From Indena Worldwide Rights To Ortataxel, A Phase 2 Third Generation Taxane
HSMN NewsFeed,
25 Jul 2007:
Biopharmaceuticals, Oncology, Licensing[Spectrum Pharmaceuticals, Indena S.p.A., ortataxel, taxane]
New Head-to-Head Study Comparing LEXIVA(R) and Atazanavir Show Similar Efficacy and Lipid Changes
HSMN NewsFeed,
25 Jul 2007:
Biopharmaceuticals, HIV/AIDS[GlaxoSmithKline, LEXIVA, fosamprenavir, ALERT Study]
Jan H. Egberts, M.D. Resigns as President and CEO of NovaDel Pharma
HSMN NewsFeed,
25 Jul 2007:
Biopharmaceuticals, Personnel[NovaDel Pharma]
Cerenis Therapeutics Announces the Addition of Three Pharmaceutical Industry Veterans to its Management Team
HSMN NewsFeed,
24 Jul 2007:
Biopharmaceuticals, Personnel[Cerenis Therapeutics]
Merrimack Pharmaceuticals Names William Slichenmyer, M.D. Senior Vice President and Chief Medical Officer
HSMN NewsFeed,
23 Jul 2007:
Biopharmaceuticals, Personnel[Merrimack Pharmaceuticals]
144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney
HSMN NewsFeed,
23 Jul 2007:
Biopharmaceuticals, HIV/AIDS[Gilead Sciences, Truvada, emtricitabine, tenofovir]
Bristol-Myers Squibb's SECURE THE FUTURE(R) Program Offers New Approach to Replicate Successful HIV Treatment Support Model
HSMN NewsFeed,
23 Jul 2007:
Biopharmaceuticals, HIV/AIDS[Bristol-Myers Squibb]
ABILIFY(R) (aripiprazole) Supplemental New Drug Application Receives Priority Review by U.S. Food And Drug Administration for Adjunctive Treatment in Adults With Major Depressive Disorder
HSMN NewsFeed,
17 Jul 2007:
Biopharmaceuticals, FDA[Bristol-Myers Squibb, Otsuka Pharmaceutical, ABILIFY, aripiprazole, depression]
Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
HSMN NewsFeed,
12 Jul 2007:
Biopharmaceuticals, Oncology[Bristol-Myers Squibb, ImClone Systems, ERBITUX, Cetuximab]
Ortec International: Dr. Costa Papastephanou Appointed CEO
HSMN NewsFeed,
11 Jul 2007:
Regenerative Medicine, Wound Care, Personnel[Ortec International, stem cell]
Synovics Pharmaceuticals Appoints Steven Getraer as Executive Vice President and Chief Financial Officer
HSMN NewsFeed,
10 Jul 2007:
Biopharmaceuticals, Personnel[Synovics Pharmaceuticals]
Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
HSMN NewsFeed,
6 Jul 2007:
Biopharmaceuticals, Oncology[Bristol-Myers Squibb, ixabepilone, metastatic breast cancer]
NicOx appoints Pascal Pfister MD as Chief Scientific Officer and strengthens R&D organization
HSMN NewsFeed,
2 Jul 2007:
Biopharmaceuticals, Personnel[NICOX]
Bristol-Myers Squibb Signs Agreement for Sale of Bufferin(R) and Excedrin(R) to Lion Corporation in Japan, Asia and Oceania
HSMN NewsFeed,
29 Jun 2007:
Biopharmaceuticals[Bristol-Myers Squibb, Lion Corporation]
Encysive Pharmaceuticals Appoints New Chief Executive and Announces Restructuring of Company Operations
HSMN NewsFeed,
25 Jun 2007:
Biopharmaceuticals, Personnel[Encysive Pharmaceuticals]
Ranbaxy Launches Pravastatin Sodium 80 Mg Tablets
HSMN NewsFeed,
25 Jun 2007:
Biopharmaceuticals, Generics[Ranbaxy Pharmaceuticals, Pravastatin, Pravachol, Bristol-Myers Squibb]
Sanofi-Aventis and Bristol-Myers Squibb Prevail in U.S. Plavix Patent Litigation
HSMN NewsFeed,
19 Jun 2007:
Biopharmaceuticals, Generics, Litigation[Bristol-Myers Squibb, Sanofi-aventis, clopidogrel, Plavix, Apotex]
FDA Grants Priority Review for Bristol-Myers Squibb's Investigational Oncology Treatment Ixabepilone
HSMN NewsFeed,
19 Jun 2007:
Biopharmaceuticals, Oncology, FDA[Bristol-Myers Squibb, ixabepilone, breast cancer]
Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia(R) (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
HSMN NewsFeed,
15 Jun 2007:
Biopharmaceuticals[Bristol-Myers Squibb, ORENCIA, abatacept, juvenile idiopathic arthritis]
DUSA Pharmaceuticals, Inc. Elects Robert F. Doman as Chief Executive Officer
HSMN NewsFeed,
14 Jun 2007:
Biopharmaceuticals, Personnel[DUSA Pharmaceuticals]
U.S. Department of Justice Investigation of Bristol-Myers Squibb in Proposed Plavix Patent Settlement Is Resolved
HSMN NewsFeed,
11 Jun 2007:
Biopharmaceuticals, Generics, Litigation[Bristol-Myers Squibb, Plavix, Apotex]
FDA Accepts and Grants Priority Review of ERBITUX(R) (Cetuximab) sBLA for Overall Survival in Patients with Advanced Colorectal Cancer
HSMN NewsFeed,
11 Jun 2007:
Biopharmaceuticals, Oncology, FDA[ImClone Systems, Bristol-Myers Squibb, ERBITUX, Cetuximab, Colorectal Cancer]
Iroko Pharmaceuticals Appoints Susan F. Langer M.D. as Chief Medical Officer and Vice President of Research & Development
HSMN NewsFeed,
7 Jun 2007:
Biopharmaceuticals, Personnel[Iroko Pharmaceuticals]
Patrick Gallagher Joins Acusphere as Senior Vice President, Business Development
HSMN NewsFeed,
7 Jun 2007:
Biopharmaceuticals, Drug Delivery, Personnel[Acusphere]
Health Canada's approval of an expanded indication for PLAVIX(R) (clopidogrel bisulfate) now offers protection from all types of heart attacks
HSMN NewsFeed,
5 Jun 2007:
Biopharmaceuticals, Cardiology, Regulatory[sanofi-aventis, Bristol-Myers Squibb, Plavix, clopidogrel]
Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
HSMN NewsFeed,
4 Jun 2007:
Biopharmaceuticals, Oncology[Pharmion, GPC Biotech, satraplatin, prostate cancer]
Phase III Ixabepilone Study Demonstrated Significant Improvement in Progression-Free Survival in Patients With Advanced Metastatic Breast Cancer
HSMN NewsFeed,
3 Jun 2007:
Biopharmaceuticals, Oncology[Bristol-Myers Squibb, ixabepilone, Metastatic Breast Cancer]
Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
HSMN NewsFeed,
3 Jun 2007:
Biopharmaceuticals, Oncology[Exelixis, XL999, non-small cell lung cancer]
Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer
HSMN NewsFeed,
2 Jun 2007:
Biopharmaceuticals, Oncology[Eli Lilly, ALIMTA, pemetrexed, non-small cell lung cancer]
Study Supports Activity of GEMZAR(R) (Gemcitabine HC1 for Injection) in the Treatment of Early-Stage Breast Cancer
HSMN NewsFeed,
2 Jun 2007:
Biopharmaceuticals, Oncology[Eli Lilly, GEMZAR, gemcitabine, breast cancer]
Millennium Appoints Three New Members to Executive Management Team
HSMN NewsFeed,
1 Jun 2007:
Biopharmaceuticals, Personnel[Millennium Pharmaceuticals]
Macroflux Names M. Cory Zwerling President, CEO
HSMN NewsFeed,
31 May 2007:
Biopharmaceuticals, Personnel[Macroflux]
Bristol-Myers Squibb Pleads Guilty to Lying to the Federal Government About Deal Involving Blood-Thinning Drug
HSMN NewsFeed,
30 May 2007:
Biopharmaceuticals, Generics, Litigation[Bristol-Myers Squibb, Plavix, clopidogrel, Apotex]
Ranbaxy Expands its Presence in the U.S. Dermatology Market Through the Acquisition of 13 Brands from Bristol Myers Squibb
HSMN NewsFeed,
29 May 2007:
Biopharmaceuticals, Dermatology, Acquisitions[Ranbaxy Pharmaceuticals, Bristol-Myers Squibb]
NCCN Updates Head and Neck Cancers Guidelines
HSMN NewsFeed,
22 May 2007:
Biopharmaceuticals, Devices, Oncology[NCCN, Head and Neck Cancer, cisplatin, Cetuximab, radiation therapy]
BARACLUDE(R) (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
HSMN NewsFeed,
21 May 2007:
Biopharmaceuticals[Bristol-Myers Squibb, BARACLUDE, entecavir, hepatitis B]
Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin in Complicated Urinary Tract Infections and Acute Pyelonephritis
HSMN NewsFeed,
19 May 2007:
Biopharmaceuticals, Urology[Ortho-McNeil, LEVAQUIN, levofloxacin, pyelonephritis, Ciprofloxacin]
Achillion Announces the Resignation of John C. Pottage, Jr., M.D., Senior Vice President and Chief Medical Officer
HSMN NewsFeed,
17 May 2007:
Biopharmaceuticals, Personnel[Achillion Pharmaceuticals]
Health Canada approves REYATAZ(R) (atazanavir sulfate) 300 mg single capsule formulation in combination therapy for adults with HIV-1 infection
HSMN NewsFeed,
17 May 2007:
Biopharmaceuticals, HIV/AIDS, Regulatory[Bristol-Myers Squibb, Bristol-Myers Squibb CANADA, REYATAZ, atazanavir]
Bristol-Myers Squibb Announces Agreement in Principle to Resolve Federal Antitrust Investigation
HSMN NewsFeed,
10 May 2007:
Biopharmaceuticals[Bristol-Myers Squibb, sanofi-aventis, Apotex, Plavix]
Poniard Pharmaceuticals Appoints Ronald A. Martell President and Chief Operating Officer
HSMN NewsFeed,
9 May 2007:
Biopharmaceuticals, Oncology, Personnel[Poniard Pharmaceuticals, Picoplatin]
Bristol-Myers Squibb Enters Cardiovascular Disease Collaboration With Isis Pharmaceuticals
HSMN NewsFeed,
9 May 2007:
Biopharmaceuticals, Licensing[Bristol-Myers Squibb, Isis Pharmaceuticals]
Bristol-Myers Squibb Joins Oslo Cancer Cluster
HSMN NewsFeed,
4 May 2007:
Biopharmaceuticals, Oncology[Bristol-Myers Squibb, Bristol-Myers Squibb Norway]
Phyton Biotech Acquires Novel Glyco-Engineering Technology, Adds Enhanced Capacity to Manufacture Therapeutic Proteins
HSMN NewsFeed,
2 May 2007:
Biopharmaceuticals, Acquisitions[Phyton Biotech, Dow Chemical Company]
James M. Cornelius Elected Bristol-Myers Squibb CEO
HSMN NewsFeed,
26 Apr 2007:
Biopharmaceuticals, Personnel[Bristol-Myers Squibb]
Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds
HSMN NewsFeed,
26 Apr 2007:
Biopharmaceuticals[Pfizer, Bristol-Myers Squibb, apixaban, Thromboembolism, deep vein thrombosis]
Lexicon Genetics Changes Name to Lexicon Pharmaceuticals as Drug Development Pipeline Progresses
HSMN NewsFeed,
26 Apr 2007:
Biopharmaceuticals[Lexicon Genetics, Lexicon Pharmaceuticals]
Acceleron Pharma Appoints James Desiderio, Ph.D. as Vice President, Program Management
HSMN NewsFeed,
25 Apr 2007:
Biopharmaceuticals, Personnel[Acceleron Pharma]
Axon Labs Names David P. Dickinson as Chief Executive Officer
HSMN NewsFeed,
24 Apr 2007:
Devices, Personnel[Axon Labs]
Exelixis Reinitiates Clinical Development of XL999 in Patients With Non-Small Cell Lung Cancer
HSMN NewsFeed,
24 Apr 2007:
Biopharmaceuticals, Oncology[Exelixis, XL999, non-small cell lung cancer]
Randomized Phase III Trial Showed ERBITUX Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
HSMN NewsFeed,
16 Apr 2007:
Biopharmaceuticals, Oncology[ImClone Systems, Bristol-Myers Squibb, EPIC study, ERBITUX, Cetuximab]
Four-Year Data Demonstrate Continued Low Incidence of BARACLUDE(R) (entecavir) Resistance in Nucleoside-naive Chronic Hepatitis B Patients
HSMN NewsFeed,
14 Apr 2007:
Biopharmaceuticals[Bristol-Myers Squibb, BARACLUDE, entecavir, hepatitis B]
BARACLUDE(R) (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment
HSMN NewsFeed,
13 Apr 2007:
Biopharmaceuticals[Bristol-Myers Squibb, hepatitis B, BARACLUDE, entecavir]
Exelixis Appoints Experienced Clinician and Scientist to Vice President of Translational Medicine
HSMN NewsFeed,
12 Apr 2007:
Biopharmaceuticals, Personnel[Exelixis]
Ranbaxy Receives Approval To Market Cefprozil Tablets and Cefprozil Powder For Oral Suspension in Canada
HSMN NewsFeed,
11 Apr 2007:
Biopharmaceuticals, Generics, Regulatory[Ranbaxy Laboratories, Cefprozil]
Data Available from ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
HSMN NewsFeed,
10 Apr 2007:
Biopharmaceuticals, Oncology[ImClone Systems, Bristol-Myers Squibb, ERBITUX, Cetuximab, pancreatic cancer]
Brian M. Gallagher Joins Transport Pharmaceuticals' Board of Directors
HSMN NewsFeed,
10 Apr 2007:
Biopharmaceuticals, Drug Delivery, Personnel[Transport Pharmaceuticals]
Alpharma Announces New Sales and Marketing Leadership in its Pharmaceuticals Business
HSMN NewsFeed,
9 Apr 2007:
Biopharmaceuticals, Personnel[Alpharma]
Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer
HSMN NewsFeed,
4 Apr 2007:
Biopharmaceuticals, Oncology[ImClone Systems, Bristol-Myers Squibb, ERBITUX, Cetuximab, head and neck cancer]
Lexicon Genetics Appoints Tamar Howson Executive Vice President of Business Development
HSMN NewsFeed,
21 Mar 2007:
Biopharmaceuticals, Personnel[Lexicon Genetics]
Exelixis Files IND Application for XL147
HSMN NewsFeed,
16 Mar 2007:
Biopharmaceuticals, Oncology[Exelixis, XL147, PI3K]
Zila, Inc. Names Lawrence A. Gyenes Chief Financial Officer
HSMN NewsFeed,
13 Mar 2007:
Devices, Diagnostics, Personnel[Zila, ViziLite]
Syneron Announces New Chief Marketing Officer
HSMN NewsFeed,
6 Mar 2007:
Devices, Personnel[Syneron Medical]
Hana Biosciences Appoints Lyn Wiesinger to Board of Directors
HSMN NewsFeed,
28 Feb 2007:
Biopharmaceuticals, Oncology, Personnel[Hana Biosciences]
Lexicon Announces Executive Management Promotions
HSMN NewsFeed,
26 Feb 2007:
Biopharmaceuticals, Personnel[Lexicon Genetics]
Bristol-Myers Squibb Consolidates its Candiac Clinical Supply Operations
HSMN NewsFeed,
26 Feb 2007:
Biopharmaceuticals[Bristol-Myers Squibb]
Bristol-Myers Squibb Company and Adnexus Therapeutics Announce Collaboration to Develop and Commercialize Innovative Oncology Compounds
HSMN NewsFeed,
26 Feb 2007:
Biopharmaceuticals, Oncology[Bristol-Myers Squibb, Adnexus Therapeutics]
Ipsen: Appointment of Stephane Thiroloix as Executive Vice-President, Corporate Development
HSMN NewsFeed,
26 Feb 2007:
Biopharmaceuticals, Personnel[Ipsen]
OncoMed Appoints Steven E. Benner, M.D., Senior Vice President and Chief Medical Officer
HSMN NewsFeed,
21 Feb 2007:
Biopharmaceuticals, Personnel[OncoMed Pharmaceuticals]
Gloucester Pharmaceuticals Appoints Pharmaceutical Veteran, Donald Hayden, as Vice-Chairman
HSMN NewsFeed,
20 Feb 2007:
Biopharmaceuticals, Personnel[Gloucester Pharmaceuticals]
Tapestry Pharmaceuticals Appoints Sandra L. Silberman, M.D., Ph.D. As Chief Medical Officer
HSMN NewsFeed,
20 Feb 2007:
Biopharmaceuticals, Personnel[Tapestry Pharmaceuticals]
Cobalis Appoints Three Pharmaceutical Industry Executives to Board
HSMN NewsFeed,
20 Feb 2007:
Biopharmaceuticals, Personnel[Cobalis]
Merck & Co., Inc. (1) To Distribute ATRIPLA(TM) in Developing Countries
HSMN NewsFeed,
16 Feb 2007:
Biopharmacetuicals, HIV/AIDS[Merck, ATRIPLA, efavirenz, emtricitabine, tenofovir]
Bristol-Myers Squibb Names Sandra Leung Senior Vice President and General Counsel
HSMN NewsFeed,
15 Feb 2007:
Biopharmaceuticals, Personnel[Bristol-Myers Squibb]
Clinical Data Supporting Development of ChemGenex's Ceflatonin(R) in Imatinib-Resistant CML Published in Cancer
HSMN NewsFeed,
14 Feb 2007:
Biopharmaceuticals, Oncology[ChemGenex Pharmaceuticals, Ceflatonin, Gleevec, chronic myeloid leukemia]
Ardea Biosciences Announces New Corporate Headquarters, New Ticker Symbol, and Appointment of Key R&D Management Team
HSMN NewsFeed,
12 Feb 2007:
Biopharmaceuticals, Personnel[Ardea Biosciences]
ImClone Systems Incorporated and Bristol-Myers Squibb Announce Application In Japan for Use of ERBITUX in Metastatic Colorectal Cancer
HSMN NewsFeed,
5 Feb 2007:
Biopharmaceuticals, Oncology, Regulatory[ImClone Systems, Bristol-Myers Squibb, ERBITUX, Cetuximab, colorectal cancer]
Veteran Pharmaceutical Executive Joins AerovectRx Corp. Board
HSMN NewsFeed,
2 Feb 2007:
Biopharmaceuticals, Personnel[AerovectRx, Jonathan Mow]
Ivrea Pharmaceuticals Appoints Daniel S. Lynch as President and Chief Executive Officer
HSMN NewsFeed,
1 Feb 2007:
Biopharmaceuticals[Ivrea Pharmaceuticals]
Icagen Announces $22 Million Financing
HSMN NewsFeed,
29 Jan 2007:
Biopharmaceuticals, Venture Capital[ Icagen]
Elixir Pharmaceuticals Names Gregory D. Perry as Chief Financial Officer
HSMN NewsFeed,
29 Jan 2007:
Biopharmaceuticals, Personnel[Elixir Pharmaceuticals]
ViaCell Appoints Kirk Williamson as Vice President of Marketing
HSMN NewsFeed,
22 Jan 2007:
Regenerative Medicine, Personnel[ViaCell]
Barr Launches Generic METAGLIP(TM) Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg
HSMN NewsFeed,
19 Jan 2007:
Biopharmaceuticals, Generics, Endocrinology[Barr Pharmaceuticals, Bristol-Myers Squibb, METAGLIP, Glipizide, Metformin]
Elixir Pharmaceuticals Presents New Data Highlighting Ghrelin Inhibition as a Potential Method for Regulating Metabolism and Treating Diabetes
HSMN NewsFeed,
17 Jan 2007:
Biopharmaceuticals, Endocrinology[Elixir Pharmaceuticals, ghrelin, diabetes]
Bristol-Myers Squibb and AstraZeneca Announce Worldwide Collaboration to Develop and Commercialize Diabetes Compounds
HSMN NewsFeed,
11 Jan 2007:
Biopharmaceuticals, Endocrinology[Bristol-Myers Squibb, AstraZeneca, Saxagliptin, diabetes]
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
HSMN NewsFeed,
10 Jan 2007:
Biopharmaceuticals, Oncology[ImClone Systems, Bristol-Myers Squibb, ERBITUX, cetuximab, mCRC]
Ambit Biosciences Appoints Wendell Wierenga, Ph.D., as Executive Vice President of Research & Development
HSMN NewsFeed,
8 Jan 2007:
Biopharmaceuticals, Personnel[Ambit Biosciences]
Exelixis Announces Senior Management Promotions
HSMN NewsFeed,
4 Jan 2007:
Biopharmaceuticals, Personnel[Exelixis]
Medarex Announces Enrollment Complete in Ipilimumab (MDX-010) Monotherapy Pivotal Registrational Trial for Metastatic Melanoma
HSMN NewsFeed,
4 Jan 2007:
Biopharmaceuticals, Oncology[Medarex, ipilimumab, MDX-010, metastatic melanoma]
Exelixis Signs Co-Development Agreement With Genentech for Small Molecule Oncology Compound
HSMN NewsFeed,
3 Jan 2007:
Biopharmaceuticals[Exelixis, Genentech, XL518]
Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Announce Exclusive Licensing Agreement for Diabetes Compound Saxagliptin in Japan
HSMN NewsFeed,
27 Dec 2006:
Biopharmaceuticals, Endocrinology, Licensing[Bristol-Myers Squibb, Otsuka Pharmaceutical, saxagliptin, diabetes]
Company Announces Acquisition of Research and Development Programs, Hiring of Senior Management Team and Name Change
HSMN NewsFeed,
22 Dec 2006:
Biopharmaceuticals, Acquisitions, Personnel[IntraBiotics Pharmaceuticals, Ardea Biosciences]
Celsion Corporation Announces New President/CEO
HSMN NewsFeed,
21 Dec 2006:
Devices, Urology, Personnel[Celsion Corporation, Prolieve, Thermodilatation]
Bristol-Myers Squibb Announces Agreement In Principle to Settle Federal Investigation Into Pricing, Sales And Marketing Practices
HSMN NewsFeed,
21 Dec 2006:
Biopharmaceuticals[Bristol-Myers Squibb]
Cadence Pharmaceuticals Initiates Pivotal Phase III Clinical Trial Evaluating Intravenous Acetaminophen for Post-Operative Acute Pain
HSMN NewsFeed,
18 Dec 2006:
Biopharmaceuticals, Surgery[Cadence Pharmaceuticals, intravenous acetaminophen, acetaminophen]
Exelixis and Bristol-Myers Squibb Sign New Collaboration Agreement to Discover and Develop Novel Oncology Compounds
HSMN NewsFeed,
18 Dec 2006:
Biopharmaceuticals, Oncology[Exelixis, Bristol-Myers Squibb]
Receptor BioLogix Names Four New Senior Executives
HSMN NewsFeed,
15 Dec 2006:
Biopharmaceuticals, Personnel[Receptor BioLogix]
96-Week Data From Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination With Sustiva(R) Published in Journal of Acquired Immune Deficiency Syndrome
HSMN NewsFeed,
15 Dec 2006:
Biopharmaceuticals, HIV/AIDS[Gilead Sciences, Viread, Emtriva, Emtriva, Sustiva, Combivir]
Robert Brown Joins Biothera as Senior Vice President, Corporate Development
HSMN NewsFeed,
14 Dec 2006:
Biopharmaceuticals, Personnel[Biothera , white blood cells]
Ranbaxy Is Granted Final Approval to Manufacture and Market Cefprozil Anti- Infective Tablets
HSMN NewsFeed,
14 Dec 2006:
Biopharmaceuticals, Generics, FDA[Ranbaxy, Cefprozil, Cefzil, Bristol-Myers Squibb]
CyDex Announces Captisol Technology Used in Recently Launched Injection Formulation of Antipsychotic Medication ABILIFY(R) (aripiprazole)
HSMN NewsFeed,
14 Dec 2006:
Biopharmaceuticals, Drug Delivery[CyDex, Captisol , ABILIFY, aripiprazole, Bristol-Myers Squibb]
OSI Pharmaceuticals Grants License to Bristol-Myers Squibb under Dipeptidyl Peptidase IV (DPIV) Patent Portfolio for the Treatment of Type 2 Diabetes
HSMN NewsFeed,
14 Dec 2006:
Biopharmaceuticals, Licensing[OSI Pharmaceuticals, Bristol-Myers Squibb, Dipeptidyl Peptidase, diabetes]
Ambit Biosciences Announces Establishment of Clinical Oncology Advisory Board
HSMN NewsFeed,
13 Dec 2006:
Biopharmaceuticals, Oncology, Personnel[Ambit Biosciences]
ABILIFY(R) (Aripiprazole) Injection for Intramuscular Use for Adults With Agitation Associated With Schizophrenia or Bipolar Mania Now Available
HSMN NewsFeed,
12 Dec 2006:
Biopharmaceuticals[Bristol-Myers Squibb, Otsuka Pharmaceutical, ABILIFY, aripiprazole]
ABILIFY(R) (aripiprazole) Demonstrated Efficacy as Long-Term Maintenance Therapy in Adults With Bipolar I Disorder Following Treatment for a Recent Manic Or Mixed Episode
HSMN NewsFeed,
7 Dec 2006:
Biopharmaceuticals[Bristol-Myers Squibb, Otsuka Pharmaceutical, ABILIFY, aripiprazole]
Medarex Announces FDA Fast Track Designations for Ipilimumab for the Treatment of Metastatic Melanoma; Fast Track Designations for First-Line Use in Combination With Chemotherapy and Second-Line Use as Monotherapy
HSMN NewsFeed,
7 Dec 2006:
Biopharmaceuticals, FDA, Oncology[Medarex, ipilimumab, MDX- 010, fast track, metastatic melanoma]
Endo Pharmaceuticals Appoints Charles Rowland as Chief Financial Officer
HSMN NewsFeed,
6 Dec 2006:
Biopharmaceuticals, Personnel[Endo Pharmaceuticals]
Ambit Biosciences Appoints Kerry Kelly, J.D., as Vice President and General Counsel
HSMN NewsFeed,
5 Dec 2006:
Biopharmaceuticals, Personnel[Ambit Biosciences]
Elixir Pharmaceuticals Raises $46 Million
HSMN NewsFeed,
28 Nov 2006:
Biopharmaceuticals, Venture Capital[Elixir Pharmaceuticals, Glufast, ghrelin agonist]
Barr's Subsidiary PLIVA Receives Approval for Pravastatin Tablets 10mg, 20mg, and 40mg and Tentative Approval for 80mg
HSMN NewsFeed,
28 Nov 2006:
Biopharmaceuticals, Generics, FDA[Barr Pharmaceuticals, PLIVA d.d., Pravastatin, PRAVACHOL, Bristol-Myers Squibb]
Elliott to Retire as President and CEO of Zimmer Holdings, Inc., Will Remain Chairman of the Board
HSMN NewsFeed,
20 Nov 2006:
Devices, Orthopaedic, Personnel[Zimmer Holdings, Zimmer]
Sonus Pharmaceuticals Announces Completion of Patient Enrollment in Phase 3 Pivotal Trial of TOCOSOL(R) Paclitaxel in Metastatic Breast Cancer
HSMN NewsFeed,
16 Nov 2006:
Biopharmaceuticals, Oncology[Sonus Pharmaceuticals, TOCOSOL Paclitaxel, metastatic breast cancer]
ChemGenex Announces Granting of Fast Track Status for Ceflatonin(R) by FDA
HSMN NewsFeed,
14 Nov 2006:
Biopharmaceuticals, Oncology, FDA[ChemGenex Pharmaceuticals, Ceflatonin, homoharringtonine, fast track designation]
Bristol-Myers Squibb Company Announces Promotion of Andrew Bonfield and Elliott Sigal to Executive Vice Presidents
HSMN NewsFeed,
14 Nov 2006:
Biopharmaceuticals, Personnel[Bristol-Myers Squibb]
ORENCIA(R) (abatacept) or REMICADE(R)(infliximab) Demonstrated Superior Efficacy to Placebo at Six Months With ORENCIA Demonstrating Both Durable Efficacy and a More Favorable Safety Profile Through 12 Months
HSMN NewsFeed,
14 Nov 2006:
Biopharmaceuticals[Bristol-Myers Squibb, ORENCIA, abatacept, rheumatoid arthritis]
ORENCIA(R) (abatacept) Data Demonstrated Improvement in Children and Adolescents With Juvenile Idiopathic Arthritis as Measured by the Validated ACR Pediatric Criteria
HSMN NewsFeed,
13 Nov 2006:
Biopharmaceuticals[Bristol-Myers Squibb, ORENCIA, abatacept, juvenile idiopathic arthritis]
Two-Year Data for ORENCIA(R) (abatacept) Demonstrate Continued Efficacy in Adults With Rheumatoid Arthritis
HSMN NewsFeed,
9 Nov 2006:
Biopharmaceuticals[Bristol-Myers Squibb, ORENCIA, abatacept, rheumatoid arthritis]
Pharmacopeia Announces the Appointment of Vice President, Clinical and Regulatory Affairs
HSMN NewsFeed,
6 Nov 2006:
Biopharmaceuticals, Personnel[Pharmacopeia]
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
HSMN NewsFeed,
6 Nov 2006:
Biopharmaceuticals, Oncology[Bristol-Myers Squibb, ImClone Systems, ERBITUX, cetuximab]
Exelixis Suspends Enrollment of New Patients in XL999 Phase II Clinical Trial Program
HSMN NewsFeed,
2 Nov 2006:
Biopharmaceuticals[Exelixis, XL999]
Panacos Appoints Scott McCallister, M.D., Chief Medical Officer
HSMN NewsFeed,
1 Nov 2006:
Biopharmaceuticals, Personnel[Panacos Pharmaceuticals]
Three-Year Data Showed Low Incidence of BARACLUDE(R) (Entecavir) Resistance in Nucleoside-Naive Chronic Hepatitis B Patients
HSMN NewsFeed,
30 Oct 2006:
Biopharmaceuticals[Bristol-Myers Squibb, BARACLUDE, entecavir, hepatitis B]
BARACLUDE(R) (Entecavir) Demonstrated Viral Suppression to Undetectable Levels in Most Patients in a Three-Year Cohort
HSMN NewsFeed,
30 Oct 2006:
Biopharmaceuticals[Bristol-Myers Squibb, BARACLUDE, entecavir, hepatitis B]
Study Shows Treatment with BARACLUDE(R) (Entecavir) Resulted in Greater Viral Load Reductions Compared to Adefovir in Antiviral Naive Chronic Hepatitis B E-Antigen Positive Patients
HSMN NewsFeed,
30 Oct 2006:
Biopharmaceuticals[Bristol-Myers Squibb, hepatitis B, BARACLUDE, entecavir]
Carl C. Icahn Appointed Chairman of ImClone Systems
HSMN NewsFeed,
25 Oct 2006:
Biopharmaceuticals, Personnel[ImClone Systems]
Par Pharmaceutical Begins Shipment of Pravastatin Tablets
HSMN NewsFeed,
23 Oct 2006:
Biopharmaceuticals, Generics, Cardiology, FDA[Par Pharmaceutical, pravastatin, Bristol-Myers Squibb, Pravachol]
FDA Approves REYATAZ(R) (atazanavir sulfate) 300 mg Single Capsule Formulation in Combination Therapy for Adults With HIV-1 Infection
HSMN NewsFeed,
20 Oct 2006:
Biopharmaceuticals, HIV/AIDS, FDA[Bristol-Myers Squibb, REYATAZ, atazanavir]
Hana Biosciences Licenses Drug Candidate for the Prevention and Treatment of EGFR Inhibitor-Associated Skin Rash
HSMN NewsFeed,
16 Oct 2006:
Biopharmaceuticals, Oncology, Licensing[Hana Biosciences, Menadione]
Michael A. Sherman Joins Endocyte as CFO
HSMN NewsFeed,
11 Oct 2006:
Biopharmaceuticals, Personnel[Endocyte]
Cardax Pharmaceuticals Appoints Fred Pashkow, MD, as EVP/CMO
HSMN NewsFeed,
9 Oct 2006:
Biopharmaceuticals, Personnel[Cardax Pharmaceuticals]
Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Submit Marketing Authorisation Application for ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) to European Medicines Agency
HSMN NewsFeed,
9 Oct 2006:
Biopharmaceuticals, Regulatory, HIV/AIDS[Bristol-Myers Squibb, Gilead Sciences, Merck, ATRIPLA]
Penwest Names Dr. Amy O'Donnell Senior Director, Clinical Development
HSMN NewsFeed,
5 Oct 2006:
Biopharmaceuticals, Personnel[Penwest Pharmaceuticals]
Transave, Inc. Appoints Renu Gupta, M.D. Chief Medical Officer
HSMN NewsFeed,
5 Oct 2006:
Biopharmaceuticals, Personnel[Transave]
Transport Pharmaceuticals Hires Vice President of Quality Systems and Operational Excellence
HSMN NewsFeed,
3 Oct 2006:
Biopharmaceuticals, Drug Delivery, Personnel[Transport Pharmaceuticals]
Published Data Show Kereos Technology Specifically Targets Arterial Plaque
HSMN NewsFeed,
29 Sep 2006:
Biopharmaceuticals, Cardiology[Kereos, atherosclerotic plaque, ligand-targeted emulsion, fumagillin]
Bristol-Myers Squibb and Gilead Sciences establish agreement to commercialize ATRIPLA(TM) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Canada
HSMN NewsFeed,
29 Sep 2006:
Biopharmaceuticals, HIV/AIDS[Bristol-Myers Squibb, Gilead Sciences, ATRIPLA , efavirenz, emtricitabine]
Bristol-Myers Squibb and Gilead Sciences Establish Agreement to Commercialize ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Canada
HSMN NewsFeed,
28 Sep 2006:
Biopharmaceuticals, HIV/AIDS[Bristol-Myers Squibb, Gilead Sciences, ATRIPLA]
Celera Identifies FCAR Genetic Polymorphism Associated with Increased Risk for Myocardial Infarction
HSMN NewsFeed,
28 Sep 2006:
Cardiology[Celera Genomics, Applera, FCAR, myocardial infarction, CARE study]
Inyx to Acquire Pharmapac UK Ltd.
HSMN NewsFeed,
28 Sep 2006:
Biopharmaceuticals, Drug Delivery, Mergers & Acquisitions[Inyx, Pharmapac UK]
Abraxis BioScience Files Marketing Application with the European Medicines Agency for ABRAXANE in the Treatment of Breast Cancer
HSMN NewsFeed,
28 Sep 2006:
Biopharmaceuticals, Oncology, Regulatory[Abraxis BioScience, ABRAXANE, paclitaxel, breast cancer]
Plavix(R) Preliminary Injunction Appeal
HSMN NewsFeed,
21 Sep 2006:
Biopharmaceuticals, Generics, Litigation[sanofi-aventis, Bristol-Myers Squibb, Apotex, PLAVIX, clopidogrel]
Thomas P. Koestler, Ph.D., Elected Head of Schering-Plough R&D
HSMN NewsFeed,
19 Sep 2006:
Biopharmaceuticals, Personnel[Schering-Plough]
Amicus Therapeutics Raises $60 Million Series D Financing; Company Also Makes Two Key Executive Appointments
HSMN NewsFeed,
14 Sep 2006:
Biopharmaceuticals, Venture Capital, Personnel[Amicus Therapeutics]
Bristol-Myers Squibb Company and Medivir AB Announce Worldwide Collaboration to Develop and Commercialize MIV-170 for the Treatment of HIV-1 Infection in Adults
HSMN NewsFeed,
13 Sep 2006:
Biopharmaceuticals, HIV/AIDS, Licensing[Medivir, Bristol-Myers Squibb, MIV-170, antiretroviral]
Bristol-Myers Squibb Board of Directors Announces Departure of Peter R. Dolan as CEO and Appointment of James M. Cornelius as Interim CEO
HSMN NewsFeed,
12 Sep 2006:
Biopharmaceuticals, Personnel[Bristol-Myers Squibb]
Icagen Reports Results of Data Monitoring Committee Meeting in Phase III Assert Trial of ICA-17043
HSMN NewsFeed,
12 Sep 2006:
Biopharmaceuticals[Icagen, ASSERT trial, hydroxyurea, sickle cell, ICA-17043]
European commission expands indication for PLAVIXŽ (clopidogrel bisulfate) offering new option for patients with most severe type of heart attack
HSMN NewsFeed,
7 Sep 2006:
Biopharmaceuticals, Cardiology, Regulatory[sanofi-aventis, PLAVIX, clopidogrel]
Baxter Names Peter Nicklin Corporate Vice President and President, Baxter Europe
HSMN NewsFeed,
7 Sep 2006:
Biopharmaceuticals, Devices, Personnel[Baxter, Peter Nicklin]
St. Francis Medical Technologies Announces Appointment of Vice President of Marketing
HSMN NewsFeed,
6 Sep 2006:
Devices, Personnel[St. Francis Medical Technologies, Matthew Frushell]
Synovics Pharmaceuticals Names Steven Getraer as CEO of Kirk Pharmaceuticals
HSMN NewsFeed,
24 Aug 2006:
Biopharmaceuticals[Synovics Pharmaceuticals, Kirk Pharmaceuticals]
FDA Approves New Indication for PLAVIX(R) (clopidogrel bisulfate) Offering New Option for Patients With Most Severe Type of Heart Attack
HSMN NewsFeed,
17 Aug 2006:
Biopharmaceuticals, Cardiology, FDA[sanofi-aventis, Bristol-Myers Squibb, PLAVIX, clopidogrel]
Bristol-Myers Squibb and Otsuka Pharmaceutical Company Launch New Rapidly Disintegrating Oral Antipsychotic Medication ABILIFY(R) DISCMELT(TM) (aripiprazole)
HSMN NewsFeed,
17 Aug 2006:
Biopharmaceuticals, Drug Delivery[Bristol-Myers Squibb, Otsuka Pharmaceutical, ABILIFY, DISCMELT, aripiprazole]
Osiris Announces Expansion of Board of Directors and Key Additions to its Senior Management Team
HSMN NewsFeed,
14 Aug 2006:
Biopharmaceuticals, Personnel[Osiris Therapeutics]
ZymoGenetics Files Lawsuit Against Bristol-Myers Squibb for Infringement of Fusion Protein Patents
HSMN NewsFeed,
14 Aug 2006:
Biopharmaceuticals, Litigation[ZymoGenetics, Bristol-Myers Squibb]
Motion Filed for Preliminary Injunction in PLAVIX(R) Patent Infringement Case
HSMN NewsFeed,
14 Aug 2006:
Biopharmaceuticals, Litigation[Bristol-Myers Squibb, Sanofi-aventis, Apotex, clopidogrel, PLAVIX]
96-Week Data from Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination with Sustiva(R) Presented at XVI International AIDS Conference
HSMN NewsFeed,
14 Aug 2006:
Biopharmaceuticals, HIV/AIDS[Gilead Sciences, Viread, Emtriva, Sustiva, Combivir]
MGI PHARMA Announces Executive Appointments
HSMN NewsFeed,
7 Aug 2006:
Biopharmaceuticals, Personnel[MGI PHARMA]
Synovics Pharmaceuticals Receives FDA Approval for Generic Version of Metformin
HSMN NewsFeed,
31 Jul 2006:
Biopharmaceuticals, Endocrinology, Generics, FDA[Synovics Pharmaceuticals, metformin, Bristol-Myers Squibb, Glucophage]
Repligen Wins Summary Judgment Against ImClone in Erbitux(R) Case
HSMN NewsFeed,
31 Jul 2006:
Biopharmaceuticals, Oncology, Litigation[Repligen, ImClone Systems, Erbitux, Cetuximab]
PLAVIX(R) Litigation Settlement Fails to Receive Antitrust Clearance From States Attorneys General
HSMN NewsFeed,
28 Jul 2006:
Biopharmaceuticals, Cardiology, Litigation[Bristol-Myers Squibb, sanofi-aventis, Apotex, PLAVIX, clopidogrel]
ConvaTec Launches Extended Pediatric Ostomy Line
HSMN NewsFeed,
28 Jul 2006:
Devices, Surgery[ConvaTec, Bristol-Myers Squibb, ostomy]
Ovarian Cancer Drug Combination Identified at Rational Therapeutics Receives FDA Approval
HSMN NewsFeed,
28 Jul 2006:
Biopharmaceuticals, Oncology, FDA[Rational Therapeutics, Bristol-Myers Squibb, Eli Lilly, Paraplatin, Gemzar]
ImClone Systems and Merck KGaA Amend and Supplement ERBITUX Agreement
HSMN NewsFeed,
20 Jul 2006:
Biopharmaceuticals, Licensing[ImClone Systems, Merck KGaA, ERBITUX]
Magen BioSciences, Inc. Announces Brian M. Gallagher Joins as President and CEO
HSMN NewsFeed,
19 Jul 2006:
Biopharmaceuticals, Personnel[Magen BioSciences]
Schering-Plough Appoints John M. Carroll Vice President, Global Internal Audits
HSMN NewsFeed,
17 Jul 2006:
Biopharmaceuticals, Personnel[Schering-Plough]
U.S. Food and Drug Administration (FDA) Approves ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), The First Once-Daily Single Tablet Regimen for Adults with HIV-1 Infection
HSMN NewsFeed,
12 Jul 2006:
Biopharmaceuticals, FDA, HIV/AIDS[Gilead Sciences, Bristol-Myers Squibb, ATRIPLA]
Schering-Plough Announces Executive Changes in Schering-Plough Research Institute
HSMN NewsFeed,
12 Jul 2006:
Biopharmaceuticals, Personnel[Schering-Plough]
Abbott and AstraZeneca Announce Collaboration to Develop and Commercialize CRESTOR(R) and Next-Generation TriCor(R) (ABT-335) Fixed-Dose Combination
HSMN NewsFeed,
5 Jul 2006:
Biopharmaceuticals, Cardiology[Abbott, AstraZeneca, CRESTOR, rosuvastatin, TriCor , fenofibrate]
FDA Approves SPRYCEL(TM) (dasatinib) With Two Indications
HSMN NewsFeed,
28 Jun 2006:
Biopharmaceuticals, Oncology, FDA[Bristol-Myers Squibb, SPRYCEL, CML, acute lymphoblastic leukemia]
Tim Ravenscroft Named President, Bristol-Myers Squibb Medical Imaging
HSMN NewsFeed,
27 Jun 2006:
Biopharmaceuticals, Personnel[Bristol-Myers Squibb]
Exelixis Appoints Experienced Biotechnology Executive as Chief Medical Officer
HSMN NewsFeed,
26 Jun 2006:
Biopharmaceuticals, Personnel[Exelixis, Gisela M. Schwab]
DUSA Pharmaceuticals Announces Election of Robert F. Doman to Board of Directors
HSMN NewsFeed,
15 Jun 2006:
Biopharmaceuticals, Personnel[DUSA Pharmaceuticals]
Isolagen Appoints Chief Financial Officer (CFO) and Senior VP - The Americas & Global Business Development
HSMN NewsFeed,
8 Jun 2006:
Regenerative Medicine, Personnel[Isolagen]
Allos Therapeutics Appoints James V. Caruso as Chief Commercial Officer
HSMN NewsFeed,
5 Jun 2006:
Biopharmaceuticals, Personnel[Allos Therapeutics]
Updated Analysis in Second-Line Treatment of Lung Cancer Trial Confirms Similar Survival for Alimta(R) and Docetaxel
HSMN NewsFeed,
4 Jun 2006:
Biopharmaceuticals, Oncology[Eli Lilly, ALIMTA , pemetrexed, non-small cell lung cancer]
Data From a Randomized Phase II Study of Dasatinib or 800 Mg/Day Imatinib- Mesylate (Gleevec(R)) Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology
HSMN NewsFeed,
3 Jun 2006:
Biopharmaceuticals, Oncology[Bristol-Myers Squibb, dasatinib, chronic myelogenous leukemia]
Bristol-Myers Squibb Issues Statement on Oncologic Drugs Advisory Committee Vote in Favor of Investigational Drug Dasatinib
HSMN NewsFeed,
2 Jun 2006:
Biopharmaceuticals, FDA[Bristol-Myers Squibb, dasatinib, chronic myeloid leukemia]
Bristol-Myers Squibb To Build New Biologics Facility In Massachusetts
HSMN NewsFeed,
1 Jun 2006:
Biopharmaceuticals[Bristol-Myers Squibb]
Alpharma Names Dean J. Mitchell President and CEO
HSMN NewsFeed,
1 Jun 2006:
Biopharmaceuticals, Personnel[Alpharma]
Bristol-Myers Squibb Extends Neuroscience Alliance With Lexicon Genetics
HSMN NewsFeed,
31 May 2006:
Biopharmaceuticals, Neurology[Lexicon Genetics, Bristol-Myers Squibb]
Abraxis BioScience Appoints New Officers to Executive Management Team
HSMN NewsFeed,
25 May 2006:
Biopharmaceuticals, Personnel[Abraxis BioScience]
Six-Month Study Evaluated Effectiveness of Aripiprazole and Standard of Care In Management of Community-Treated Patients with Schizophrenia
HSMN NewsFeed,
25 May 2006:
Biopharmaceuticals[Bristol-Myers Squibb, Otsuka Pharmaceutical, aripiprazole, schizophrenia]
Icagen Names Senior Vice President Clinical and Regulatory Affairs
HSMN NewsFeed,
25 May 2006:
Biopharmaceuticals, Personnel[ Icagen]
96-Week Viral Suppression Data From Two Studies Presented for BARACLUDE(R) (entecavir) in Chronically-Infected Hepatitis B Patients
HSMN NewsFeed,
23 May 2006:
Biopharmaceuticals[Bristol-Myers Squibb, BARACLUDE, entecavir, hepatitis B]
Bristol-Myers Squibb Announces Discontinuation of Development of Muraglitazar, an Investigational Oral Treatment for Type 2 Diabetes
HSMN NewsFeed,
18 May 2006:
Biopharmaceuticals, Endocrinology[Bristol-Myers Squibb, muraglitazar, diabetes]
MorphoSys and Schering-Plough Sign R&D Agreement
HSMN NewsFeed,
17 May 2006:
Biopharmaceuticals[MorphoSys , Schering-Plough, Combinatorial Antibody Library, HuCAL]
ImClone Systems Names Elizabeth Yamashita Vice President, Regulatory CMC and Operations
HSMN NewsFeed,
16 May 2006:
Biopharmaceuticals, Personnel[ImClone Systems]
ABILIFY(R) (Aripiprazole) Demonstrated Efficacy as Maintenance Therapy In Adults with Bipolar I Disorder Following Treatment for a Recent Manic or Mixed Episode
HSMN NewsFeed,
16 May 2006:
Biopharmaceuticals[Bristol-Myers Squibb, Otsuka Pharmaceutical, ABILIFY, aripiprazole]
Seattle Genetics Names Pamela Trail, Ph.D., as Chief Scientific Officer
HSMN NewsFeed,
16 May 2006:
Biopharmaceuticals, Personnel[Seattle Genetics]
Journal of Burn Care & Research Reports AQUACEL(R) Ag Hydrofiber(R) Dressing Demonstrated Benefits Over Silver Sulfadiazine in Managing Patients with Partial Thickness Burns
HSMN NewsFeed,
15 May 2006:
Devices, Wound Care[ConvaTec, Bristol-Myers Squibb, AQUACEL, Ag Hydrofiber, silver sulfadiazine]
William Kelly Joins Inyx in the New Position of Vice President -- Investor Relations & Corporate Communications
HSMN NewsFeed,
9 May 2006:
Biopharmaceuticals, Personnel[Inyx]
U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) Supplemental Biologics License Application (sBLA) for Third-Party Manufacturing Facility Lonza Biologics Inc.
HSMN NewsFeed,
5 May 2006:
Biopharmaceuticals, FDA[Bristol-Myers Squibb, Lonza Biologics, ORENCIA, abatacept, rheumatoid arthritis]
Bristol-Myers Squibb and Gilead Sciences Submit New Drug Application to U.S. FDA for a Once-Daily Single Tablet Regimen of Sustiva(R) (Efavirenz) and Truvada(R) (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Treatment
HSMN NewsFeed,
27 Apr 2006:
Biopharmaceuticals, HIV/AIDS, FDA[Gilead Sciences, Bristol-Myers Squibb, Sustiva, efavirenz, Truvada]
Watson Pharmaceuticals Launches Pravastatin Tablets
HSMN NewsFeed,
25 Apr 2006:
Biopharmaceuticals, Generics[Watson Pharmaceuticals, Bristol-Myers Squibb, Pravachol, pravastatin]
Teva Receives First FDA Approval for Generic Pravachol(R)
HSMN NewsFeed,
25 Apr 2006:
Biopharmaceuticals, Generics, FDA[Teva Pharmaceutical, Pravachol, Bristol-Myers Squibb, Pravastatin]
Teva Provides Update on Generic Pravachol(R)
HSMN NewsFeed,
21 Apr 2006:
Biopharmaceuticals, Generics, Litigation[Teva Pharmaceutical, Pravachol, Bristol-Myers Squibb, Pravastatin]
Teva Announces Stay of Approval for Generic Pravachol Lifted
HSMN NewsFeed,
20 Apr 2006:
Biopharmaceuticals, Generics, Litigation[Teva Pharmaceutical, Pravachol, Bristol-Myers Squibb, Pravastatin, Apotex]
District Court Denies Apotex's Request to Block Teva's Introduction of First Generic Pravachol(R) In The U.S.
HSMN NewsFeed,
19 Apr 2006:
Biopharmaceuticals, Generics, FDA, Litigation[Teva Pharmaceutical, Apotex, pravastatin, Bristol-Myers Squibb, Pravachol]
Jay Speelhoffer Promoted to Vice President, Sales, HEALTHPOINT Tissue Management
HSMN NewsFeed,
19 Apr 2006:
Devices, Personnel[HEALTHPOINT]
Bristol-Myers Squibb Company Names David I. Johnson President of ConvaTec
HSMN NewsFeed,
17 Apr 2006:
Devices, Biopharmaceuticals, Personnel[Bristol-Myers Squibb, ConvaTec]
Phyton Biotech, Inc., a DFB Pharmaceuticals Affiliate, Signs Licensing Agreement with DiAthegen LLC to Commercialize Growth Hormone Receptor Antagonist That Treats Acromegaly, Cancer, Diabetes
HSMN NewsFeed,
11 Apr 2006:
Biopharmaceuticals[Phyton Biotech, DFB Pharmaceuticals, DiAthegen]
New River Pharmaceuticals Names John Thottathil Chief Scientific Officer
HSMN NewsFeed,
11 Apr 2006:
Biopharmaceuticals, Personnel[New River Pharmaceuticals]
Inflammatory-Enzyme Shown to Predict Risk of Cardiovascular Events After Acute Coronary Syndromes
HSMN NewsFeed,
11 Apr 2006:
Biopharmaceuticals, Diagnostics, Cardiology[GlaxoSmithKline, lipoprotein-associated phospholipase A2]
Glades Pharmacueticals Appoints Darren Alkins, President
HSMN NewsFeed,
11 Apr 2006:
Biopharmaceuticals, Personnel[Glades Pharmaceuticals]
DUSA Announces Hiring of William F. O'Dell as Executive Vice President, Sales and Marketing
HSMN NewsFeed,
10 Apr 2006:
Biopharmaceuticals, Personnel[DUSA Pharmaceuticals]
Neuronetics Prepares for Market Launch of New Depression Therapy; Hires Peter Anastasiou as Vice President, Marketing
HSMN NewsFeed,
10 Apr 2006:
Devices, Neurology, Personnel[Neuronetics, neuromodulation, Transcranial Magnetic Stimulation]
Vitae Pharmaceuticals Appoints Industry Veteran, Donald Hayden, as Chairman
HSMN NewsFeed,
6 Apr 2006:
Biopharmaceuticals, Personnel[Vitae Pharmaceuticals]
Pharmacopeia Licenses Novel Therapeutic Candidates From Bristol-Myers Squibb
HSMN NewsFeed,
3 Apr 2006:
Biopharmaceuticals, Licensing[Pharmacopeia, Bristol-Myers Squibb]
ImClone Systems Announces Receipt of $250 Million Milestone Payment from Bristol-Myers Squibb
HSMN NewsFeed,
3 Apr 2006:
Biopharmaceuticals, Oncology[ImClone Systems, Bristol-Myers Squibb, ERBITUX, Cetuximab]
Medarex Announces Initiation of Registrational Trial for Ipilimumab (MDX-010) as Monotherapy in Previously-Treated Metastatic Melanoma Patients
HSMN NewsFeed,
31 Mar 2006:
Biopharmaceuticals, Oncology[Medarex, Bristol-Myers Squibb, ipilimumab, MDX-010, metastatic melanoma]
Apotex Announces Agreement to Settle U.S. PLAVIX(R) Litigation
HSMN NewsFeed,
22 Mar 2006:
Biopharmaceuticals, Generics, Litigation[Apotex, sanofi-aventis, Bristol-Myers Squibb, PLAVIX, clopidogrel]
Sanofi-aventis and Bristol-Myers Squibb Announce Agreement to Settle U.S. PLAVIX(R) Litigation with Apotex Subject to Certain Conditions
HSMN NewsFeed,
21 Mar 2006:
Biopharmaceuticals, Litigation[Bristol-Myers Squibb, sanofi-aventis, Apotex, clopidogrel, PLAVIX]
Teva Provides Update on Generic Pravachol Exclusivity
HSMN NewsFeed,
16 Mar 2006:
Biopharmaceuticals, Generics[Teva Pharmaceutical, pravastatin, Pravachol, Bristol-Myers Squibb]
New Study Furthers Understanding of the Role of Dual Antiplatelet Therapy in the Prevention Of Atherothrombotic Events, Including Heart Attack, Stroke or Cardiovascular Death in Broad Population
HSMN NewsFeed,
12 Mar 2006:
Biopharmaceuticals, Cardiology[Bristol-Myers Squibb, sanofi-aventis, CHARISMA, Clopidogrel, Plavix, Iscover]
Allos Therapeutics Appoints Paul L. Berns as President and CEO
HSMN NewsFeed,
10 Mar 2006:
Biopharmaceuticals, Personnel[Allos Therapeutics]
Inotek Pharmaceuticals hires Emma Reeve as Chief Financial Officer
HSMN NewsFeed,
9 Mar 2006:
Biopharmaceuticals, Personnel[Inotek Pharmaceuticals]
U.S. FDA Grants Traditional Approval for Gilead's Once-Daily HIV Medications Truvada(R) and Viread(R)
HSMN NewsFeed,
8 Mar 2006:
Biopharmaceuticals, HIV/AIDS, FDA[Gilead Sciences, Viread, tenofovir, Truvada, emtricitabine]
FDA Grants Priority Review for Bristol-Myers Squibb's Investigational Oncology Treatment Dasatinib
HSMN NewsFeed,
7 Mar 2006:
Biopharmaceuticals, Oncology, FDA[Bristol-Myers Squibb, dasatinib, chronic myelogenous leukemia]
Recent FDA Action Validates ADVEXIN(R) Registration Strategy; Introgen Encouraged By Approval of Erbitux(R) for Head and Neck Cancer
HSMN NewsFeed,
3 Mar 2006:
Biopharmaceuticals, Oncology, FDA[Introgen Therapeutics, ADVEXIN, p53, Erbitux, Centuximab, Bristol-Myers Squibb]
FDA Approves ERBITUX(R) (Cetuximab) for Treatment of Head and Neck Cancer
HSMN NewsFeed,
1 Mar 2006:
Biopharmaceuticals, Oncology, FDA[ImClone Systems, Bristol-Myers Squibb, ERBITUX, Cetuximab, head and neck cancer]
Fredrick D. Cobb Appointed Vice President of Finance at Advaxis
HSMN NewsFeed,
28 Feb 2006:
Biopharmaceuticals, Personnel[Advaxis]
U.S. Food and Drug Administration Approves EMSAM(R) (selegiline transdermal system), the First Transdermal Patch for the Treatment of Major Depressive Disorder
HSMN NewsFeed,
28 Feb 2006:
Biopharmaceuticals, Drug Delivery, FDA[Bristol-Myers Squibb, Somerset Pharmaceuticals, EMSAM, selegiline transdermal]
Michael Adam, Ph.D. to Join Anadys Pharmaceuticals as Senior Vice President, Development Operations
HSMN NewsFeed,
22 Feb 2006:
Biopharmaceuticals, Personnel[Anadys Pharmaceuticals]
American Pharmaceutical Partners Receives FDA Approval for Carboplatin Injection, 600 mg
HSMN NewsFeed,
17 Feb 2006:
Biopharmaceuticals, Generics, FDA[American Pharmaceutical Partners, Carboplatin, Bristol-Myers Squibb, Paraplatin]
ImClone Systems Announces Complete Enrollment of Several Studies Examining Potential Survival Benefit Of ERBITUX(R) In Three Major Cancer Types
HSMN NewsFeed,
16 Feb 2006:
Biopharmaceuticals, Oncology[ImClone Systems, ERBITUX, cetuximab, colorectal cancer, head and neck cancer]
Vitae Pharmaceuticals Hires Tina Fiumenero as Senior Vice President, Finance and Administration
HSMN NewsFeed,
16 Feb 2006:
Biopharmaceuticals, Personnel[Vitae Pharmaceuticals]
GenVec Names Russell Wesdyk Vice President of Business Development and Strategic Planning
HSMN NewsFeed,
14 Feb 2006:
Biopharmaceuticals, Personnel[GenVec]
ImClone Systems Promotes Richard Crowley to Senior Vice President, Biopharmaceutical Operations
HSMN NewsFeed,
9 Feb 2006:
Biopharmaceuticals, Personnel[ImClone Systems]
XYOTAX(TM) has FDA Fast Track Designation for Women With Advanced Lung Cancer Who are Performance Status 2
HSMN NewsFeed,
8 Feb 2006:
Biopharmaceuticals, FDA, Oncology[Cell Therapeutics, XYOTAX, Taxol, fast track designation, NSCLC]
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. Announce Availability of 2 mg ABILIFY(R) (aripiprazole) Tablet and Nonrefrigerated Oral Solution
HSMN NewsFeed,
7 Feb 2006:
Biopharmaceuticals[Bristol-Myers Squibb, Otsuka Pharmaceutical, ABILIFY, aripiprazole]
Ambit Biosciences Appoints Donald R. Myll Senior Vice President Commercial Operations and Chief Financial Officer
HSMN NewsFeed,
26 Jan 2006:
Biopharmaceuticals, Personnel[Ambit Biosciences]
Bristol-Myers Squibb Announces Litigation Reserve
HSMN NewsFeed,
23 Jan 2006:
Biopharmaceuticals, Litigation[Bristol-Myers Squibb, VANLEV, omapatrilat]
Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of Combination HIV Therapy Published in New England Journal of Medicine
HSMN NewsFeed,
18 Jan 2006:
Biopharmaceuticals, HIV/AIDS[Gilead Sciences, Viread, tenofovir disoproxil, Emtriva, Truvada]
FDA Grants Priority Review to PLAVIX(R) (Clopidogrel Bisulfate) Supplemental New Drug Application (sNDA) for Additional Type of Heart Attack
HSMN NewsFeed,
18 Jan 2006:
Biopharmaceuticals, Cardiology, FDA[sanofi-aventis, Bristol-Myers Squibb, PLAVIX, STEMI , clopidogrel]
Gerald W. Bruce Joins NitroMed as Vice President, Sales
HSMN NewsFeed,
17 Jan 2006:
Biopharmaceuticals, Personnel[NitroMed, BiDil]
Sapphire Therapeutics, Inc. Appoints New Director and Scientific Advisory Board to Support Oncologic and Metabolic Pipeline Development
HSMN NewsFeed,
17 Jan 2006:
Biopharmaceuticals, Personnel[Sapphire Therapeutics]
FDA Approves Taclonex(R) - Once Daily Therapy for Treatment of Psoriasis
HSMN NewsFeed,
10 Jan 2006:
Biopharmaceuticals, Dermatology, FDA[Warner Chilcott, LEO Pharma, Taclonex, calcipotriene, betamethasone, psoriasis]
Elan and EntreMed Execute License Agreement for Proprietary NanoCrystal(R) Technology
HSMN NewsFeed,
10 Jan 2006:
Biopharmaceuticals, Licensing, Oncology, Drug Delivery[Elan , EntreMed, Panzem]
Genentech Announces Vice President Appointments in Commercial Operations, Corporate Information Technology, Product Development and Product Operations
HSMN NewsFeed,
9 Jan 2006:
Biopharmaceuticals, Personnel[Genentech]
Bristol-Myers Squibb and Gilead Announce Data Supporting Bioequivalence for Single-Pill Fixed-Dose Regimen of Sustiva(R) (efavirenz) and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate)
HSMN NewsFeed,
9 Jan 2006:
Biopharmaceuticals, HIV/AIDS[Gilead Sciences, Bristol-Myers Squibb, Sustiva, Truvada]
CancerVax and Micromet Announce Merger Agreement
HSMN NewsFeed,
9 Jan 2006:
Biopharmaceuticals, Mergers & Acquisitions[CancerVax, Micromet AG]
Mpex Pharmaceuticals Appoints Matthew A. Wikler to the Position of Chief Medical Officer
HSMN NewsFeed,
6 Jan 2006:
Biopharmaceuticals, Personnel[Mpex Pharmaceuticals]
Repligen Files Infringement Complaint Against Bristol-Myers Squibb for Orencia(R)
HSMN NewsFeed,
6 Jan 2006:
Biopharmaceuticals, Litigation[Repligen, Bristol-Myers Squibb, Orencia, CTLA4-Ig, rheumatoid arthritis]
CyDex, Inc. Names Jose L. Rodriguez Vice President of Business Development
HSMN NewsFeed,
5 Jan 2006:
Biopharmaceuticals, Personnel[CyDex]
Endocyte Signs Agreement with Bristol-Myers Squibb to Develop and Commercialize Folate-Targeted Chemotherapeutic Agents
HSMN NewsFeed,
5 Jan 2006:
Biopharmaceuticals, Oncology, Licensing[Endocyte, Bristol-Myers Squibb, epothilone]
Kosan Names Albert L. Kraus, Ph.D., Vice President of Regulatory Affairs
HSMN NewsFeed,
5 Jan 2006:
Biopharmaceuticals, Personnel[Kosan Biosciences]
Bristol-Myers Squibb Company Announces Submission of ORENCIA(R) (abatacept) Supplemental Biologics License Application to the U.S. Food and Drug Administration
HSMN NewsFeed,
3 Jan 2006:
Biopharmaceuticals, FDA[Bristol-Myers Squibb, ORENCIA, abatacept, rheumatoid arthritis]
ImClone Systems Names Cheryl Anderson Vice President, Regulatory Affairs
HSMN NewsFeed,
3 Jan 2006:
Biopharmaceuticals, Personnel[ImClone Systems]
Additional items found: The Network Archive contains
500 additional itemsBristol-Myers Squibb
Public
Feeds 
Full text >>